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CHAPTER 1 
INTRODUCTION TO SOMATOSTATIN IN INTESTINAL 
INFLAMMATION 
Chapter 2 
Introduction 
Since Dr Smethurst in 1859 was prosecuted for poisoning Mrs Ballks, who 
apparently suffered fj'Oln Crohn's disease', there have been many different 
theories about the nature of inflammatory bowel disease (!BD). The concept of 
idiopathic ulcerative colitis in the late 19th century' and its differentiation from 
idiopathic regional ileitis, later known as Crohn's disease', only appeared in the 
last hundred years. Much has still to be learned about the etiology and 
pathogenesis of these diseases. Before 1970, genetic factors or hypersensitivity to 
certain unknown micro-organisms or toxic agents were poshdated4) and these 
concepts have not as yet been refuted"'. 
TABLE 1.1 Clinical presentation of acute IBD. Signs and symptoms depend on the bowel 
part involved. In Crohn's disease, lesions may be found in the entire digestive tract from mouth 
to anus. Ulcerative colitis only involves colonic segments. 
Crohll's disease 
abdominal pain 
diarrhoea, usually non-bloody 
steatorrhoea 
weight loss, anorexia, malaise 
enteric fistula, abdominal mass 
extra-intestinal symptoms: 
10 
Fever 
arthralgia f arthritis 
eI)1hema nodosum 
pyodemla gangrenosul11 
stomatitis aphthosa 
anal fissure, fistula or abscess 
iritis f uveitis 
chronic fatigue 
jaundice 
Ulcerative colitis 
diarrhoea 
rectal frequency 
gross blood in stool 
passage OflllllCOpUS 
abdominal pain, rectal cramps 
extra-intestinal symptoms: 
fever 
arthralgia I arthritis 
pyoderma gangrenosum 
iritis f uveitis 
Introduction 
In the last two decades, research has concentrated on elements of the intestinal 
immune system in the pathogenesis ofIBD. 
Despite different clinical and histological manifestations, ulcerative colitis and 
Crohn's disease have many common features (TABLE 1.1). In both disorders 
intestinal damage appcars to be immunologically mediated9,w. An inflammatory 
cascade is initiated by unknown stimuli which activate macrophages and 
intraepithelial T-lymphocytes (FIGURE l.1)1I,!2, The immune reaction is 
augmented by recl1litment of other inflammatory cells and production of 
cytokines and other mediators including eicosanoids, adhesion molecules and 
chemokines 13-18_ Due to an unknown disturbance in the imlllune response in IBD 
patients these inflammatory reactions do not subside, but result in sustained 
mucosal injury. A pro-inflammatory role has been attributed to the T-helper 
lymphocyte, as its depletion prevents IBD exacerbation!9. A reduced suppressor 
T-cell proliferation in IBD mucosa may also contribute to this ongoing intestinal 
inflammation2o. 
Although much is known about the clinical and epidemiological characteristics 
and the sequelae of intestinal inflammation and inmmne cascades, many 
pathogenic aspects of inflanullatory bowel disease are still unidentified. As 
mentioned above, much attention has been paid to the role of leukocytes, 
cytokines and secondary inflallllllatory mediators. None of these factors seems to 
be of sole importance. Apart 1i-0I11 activity of the primary umllune cells, other 
constituents of the intestinal wall contribute to inflammation. Recent research has 
focussed on the interaction between the illllllune system and mucosal epithelial 
cells, vascular endothelium, intestinal smooth nmscle and nerve cells21 .22 . 
Intestinal smooth muscle cells are capable of cytokine productiOll1, and 'play an 
inlportant role in fibrosis and stricture formation, and in the disturbed gut 
motility, resulting in diarrhoea and abdominal cramps. 
11 
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FIGURE 1.1 Schematic overview of immunologic events in mucosal inflammation in IBD: unkrlO\\1l 
stimuli activate intestinal mucosal macrophages, which produce several C)1okines. Interleukin-l (IL-I) 
stimulates T-helper (TH)-lymphocyte activity and differentiation into TH! and Ttl2 cells. In addition, T-
helper lymphocyte stimulation occurs through antigen presenting cells (APe), mediated by IL-12. 
Positive and negative feedback mechanisms trom TH cell subsets regulate imlllunocyte activity and extent 
of inflammation. These autoregulatory circuits are disturbed in lBD, resulting in perpetuating 
inflammation. Balance between apoptosis and diflerentiation is important for feedback in the 
inflammatory cascade. 
Modifie-dafter: Kirsner JB, Shorter RG (eds.) llljlollllllotorybolrel disease. Williams & Wilkins, Baltimore, 1995. 
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Introduction 
The nervous system also has an impact on intestinal inflannnation (FIGURE 1.2), 
Since the begimling of the 20th century, several reports on influence of central 
and peripheral nervous system on inflannnatory processes have appeared'4, The 
interaction of brain, neuroendocrine system (hypothalamus, pituitary gland, 
adrenals) and immune system is well known in several disorders like asthma and 
. 25-27 
sepSIS . 
The neuroimmune relationship has also been studied in several models of 
intestinal inflammation"'''']O, Most evidence for neuropeptide control of 
intestinal immunity evolves from indirect arguments, like the proximity of fine, 
neuropeptide-containing nervous filaments near the intestinal immune 
system29.JI, Conflicting results emerge from in vitro studies, This is illustrated by 
intestinal wall substance P receptor density, which has been repOlted to be 
increased in IBD32,33, whereas the number of substance P and vasoactive 
intestinal peptide containing nerves is decreased in colonic mucosa sections with 
active inflannnationJ4 , The level of substance P and calcitonin gene-related 
peptide in intestinal mucosa and muscle layers drops during the course of 
experimental colitisJ', Pro- as well as anti-inflammatory actions ofneuropeptides 
have been describedJO In addition, intestinal inflammatory cells are capable of 
producing neuropeptides for local immunoregulatory activiti6, 
FIGURE 1.2 Neuroinflammation. Relationship between ncrvous and endocrine system, immune 
systcm and effector cells. Communication (double arrow) through neurotranslllittors, neuropeptides, 
honnones, cytokines, eicosanoids and other soluble mediators. 
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Somatostatin (SMS) is one of the commonest neUl'opeptides. Most of the body 
SMS content is stored in the digestive tract37. SMS exeiis inhibitory actions on 
pancreas and intestinal secretion, gut motility and splanchnic bloodflowJ8 . 
Moreover, SMS has several ilmnune regulatOlY properties and may have a 
beneficial effect on intestinal inflannnation39•4o • Cunently, this key inhibitory 
neUl'opeptide and its long-acting analogue octreotide are applied as therapeutic 
agents in several intestinal diseases, like variceal bleeding of the oesophagus, 
intractable dianhoea and intestillal fistulae41 .42. However, despitc some optimistic 
augUl'ies, their role ill the management of inflammatory bowel disease still has to 
be defined43 ,44. 
Aim of the study 
The research described in this thesis is aimed at examining the role of 
somatostatin (SMS) in several aspects of intestinal inflannnatory processes and 
its possible therapeutic use. The literature on SMS involvement in intestinal 
inflammation is reviewed in chapter 2. 
The main reason to stmi this series of studies was a report of beneficial effects of 
SMS on acute acetic acid-induced colitis in rats3 •. In view of the potential clinical 
advantages of SMS over the available drugs for patients with corticosteroid-
resistant severe colitis, we decided to perform simultaneously a clinical 
therapeutic trial and some animal experiments, rather than to wait for the results 
of Oul' experimental studies prior to clinical trials. There is an extensive 
experience with SMS and its analogue octreotidc in clinical disorders, and these 
drugs have a remarkable lack of side effects. We studied the influence of SMS 
and its long-acting analogue octreotide on acute and non-acute inflammation in 
another model of murine colitis (dextran sulphate sodium-induced)", expecting 
14 
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to find inhibition of mucosal inflammatory changes and diminished mucosal 
concentrations of pro inflammatory cytokines (Ch. 3 and 4). 
SMS is at present used in the management of diarrhoeal and motility disorders of 
different catISes.J6,47. As disturbed motility occurs in intestinal inflammation, an in 
vitro shldy was performed on the reactivity of colon smooth muscles in murine 
dextran sulphate sodium-induced colitis. This study was aimed at detecting 
increased susceptibility of colon smooth muscle to prokinetic agents during 
inflammation and a possible inhibiting effect of SlvIS (Ch. 5). 
Gut wall SMS receptor density has been reported to be increased in IBD48. We 
performed octreotide scintigraphy in active IBD in order to visualise these 
receptors in vivo. A new immunohistochcmic technique was applied to intestinal 
specimens to localise these receptors in vitro (Ch. 6). 
Based on the reported immune inhibitory effects of SMS and the beneficial 
effects on experimental intestinal inflammation]9 .• o, a clinical application for 
octreotide was sought in a multicenter trial in active ulcerative colitis (Ch. 7). 
All rcsults are discussed in the general discussion of the thesis and perspective 
for the relevance of this research is given (Ch. 8). 
IS 
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SOMATOSTATIN IN INFLAMMATORY BOWEL DISEASE 
JD.van Bergeijk, J.H.P.Wilson 
III adapted form ji'OllZ lvIediators of II!flammatiolZ 1997;6:303-9 
Chapter 2 
Abstract 
Various immunolllodulating cells, interacting by molecular mediators control 
intestinal inflannnation. Neuropeptides, released by enteric nerve cells and 
neuroendocrine mucosa cells, are able to affect several aspects of the general and 
intestinal immune system, with both pl'O- as well as anti-inflammatory activities. 
In inflammatory bowel disease (IBD) there is both mOlllhological as well as 
experimental evidence for involvement of nelll'opeptides in the pathogenesis. 
Somatostatin is the main inhibitory peptide in inflammatory processes, and its 
possible role in IBD is discussed. 
20 
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Introduction 
Ulcerative colitis and Crohn's disease are both characterised by chronic, 
relapsing intestinal inflammation. The etiology of both forms of inflammatory 
bowel disease (IBD) is still unknown, despite intensive research in two main 
areas - abnormal regulation of the local immune response and exogenous factors, 
including infectious agents. The gastrointestinal immune system protects the 
organism against toxins, micro-organisms and dietary antigens within the gut 
lumen. It is generally assumed that luminal stimuli presented to intestinal mucosa 
activate intra-epithelial iUllnunocytes resulting in release of mediators of 
inflammation. In IBD an inflammatory cascade is initiated and, due to 
insufficient or inappropriate immune reactions, intestinal damage results'·2. The 
reasons for inappropriate immune activation are unknown. Central roles are 
currently ascribed in this process to activated intestinal macrophages and T-
lymphocytes2 in combination with an imbalance between pro- and contra-
inflammatory T-cells l .'. Treatment ofIBD is aimed at reducing the production or 
action of mediators of inflammation (TABLE 2.1). 
Delicate interactions of intestinal mucosal epitheliulll, smooth muscle cells, gut 
wall blood vessel endotheliulll, immunocytes and enteric nerve cells contribute to 
and regulate intestinal inflammatory changes. These processes are mediated by 
various chemical messengers, most of which are produced by lymphocytes, 
granulocytes and macrophages. Recent studies on etiopathogenesis and treatment 
in IBD have concentrated on these immunocyte products which include 
cytokines, eicosanoids and adhesion molecules. The contribution of other 
clements of the gastrointestinal immunological defence system to chronic 
intestinal inflammation is less well known. A potcntially interesting area is the 
inullunoregulatory role of the enteric nerves and neuroendocrine cells. 
Neuropeptides, like substance P (SP), somatostatin (SMS), vasoactive intestinal 
peptide (VIP) and calcitonin gene related peptide (CGRP), are the molecular 
21 
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mediators of neuroregulation of the intestinal immune system, providing for 
interactions between nervous system and inununocytes. 8MS is a key inhibiting 
factor of many biological processes. In this review the role of SMS as 
neuroinllnune modulator in IBD will be highlighted, together with its possible 
future use in the treatment ofIBD. 
TABLE 2.1 Examples of drugs used in treatment of IBD. 
aminosalicylates 
corticosteroids 
immunomodulatoryagents 
immunomodulatoryagents, 
experimental use 
conmlOll dmgs under investigation 
sulfasalazine 
• 5-aminosalicylic acid 
old: prednisone I prednisolone 
• new: budesonide I becIomethasone 
• azathioprine 16-mercaplopurine 
• cyclosporine 
• FK506 
methotrexate 
anti-tumour necrosis factora 
• interleukin- 10 
• antibiotics 
• heparin 
IransdernHli nicotine 
lidocaine 
Neuroinflammation, neuropeptides and intestinal 
inflammation 
The concept of neuroinllllune interaction is in part derived liOln older clinical 
observation that inflammatory processes are influenced by emotional or physical 
stress. The immune system is subject to central nervous control and Pavlovian 
responses6. Although IBD patients do not have more emotional difficulties or 
22 
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psychosocial stress compared to a normal population, disease activity and 
response to therapy are celiainly influenced by the state of mental well-being'. 
The interaction between nervous system and the intestinal immune system is 
probably mediated by neuropeptides derived liOlll enteric nerves and 
neuroendocrine cellsS-11 , 
I"lembrane-bound nemopeptide receptors are found on several immunoc)1es, 
including T-Iymphocytes and monocytes'·9.12.!6. Various nemopeptides affect 
intestinal lymphocyte nmction and several cells of the intestinal inmllme system 
also produce nemopeptides, suggesting a local inllllunoregulatory task!'·20. 
Migration of inllllunocytes into the intestinal mucosa is affected by 
'd 2! neuropeptr es , 
In addition there are several morphological arguments that suggest neuropeptide 
involvement in intestinal lllucosal immunity, Intestinal mucosa contains SP) VIP 
and srvIS immunoreactive nerve fibres and co-localisation is COllUl1on22,23 
Nemopeptides show a specific distribution along the gut. Transmural distribution 
can be different for different nemopeptides24•27 • 
The reported studies of nemopeptide inllllunomodulation in the intestine need to 
bc interpreted with some caution. Receptor binding studies often show 
unexpected concentration relationships and depend strongly on the local 
conditions"'''. Autoradiography is a semiquantitative approach and sampling 
elTor in taking mucosal biopsies or loss of neuropeptide containing cells by 
inflammatory damage, may account for some of the confusing results, Structural 
and species specific nemopeptide receptor heterogeneity may fmther complicate 
comparison of results"·l'. Nemopeptides are known to exert different effects at 
different sites. For instance skin mast cells are susceptible to SMS, whereas SMS 
docs not induce histamine release /i'om intestinal mast cellsl'. 
23 
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Neuropeptides may be 1'1'0- or anti-inflammatory. Generally, substance P (SP) 
has a pro-inflanunatory action. Macrophage interleukin-l (IL-l) production and 
cytotoxicity is stimulated by Sp20•40 as is lL-l, tumour necrosis factor (TNF)-a 
and IL-6 release by human mOllocytes3l . SP stimulates proliferation of and 
immunoglobulin synthesis by lymphocytes fi'om spleen, mesenteric lymph nodes 
and Peyer's patches". Moreover, in experimental infection with Schistosoma 
mallsolli SP induces interferon (IFN)-y production by granuloma macrophages41 . 
However, a dose-dependent inhibition of immunoglobulin production of murine 
intestinal granuloma derived B-cells has been described". Some of these pro-
inflammatory effects of SP are opposed by SMS. SMS inhibits macrophage SP-
induced IFNy release41 . SP-induced chemotaxis ofneutrophils can be completely 
reversed by the SMS analogue octreotide43 • 
In mucosal lymphocytes from resected human colon segments, DNA synthesis as 
measured by 'H-thymidine uptake, is inhibited by low concentrations of SMS, 
VIP, SP and bombesin". Tllis inhibition might be principally achieved by T-cell 
suppression, as observed in lymphocytes that are stimulated by concanavalin A. 
The maximum inllibitory effects are obtained after 4 days of neuropeptide 
incubation". VIP and SMS inhibit lymphocytic proliferation in a dose-dependent 
fashion I7•28•29,45. The inhibitory effects of VIP and SMS on these lymphocytes are 
mediated by specific receptors, not by cytotoxicity"'''. 
VIP has both pro- and anti-inflammatory effects on intestinal T-cells and 
macrophages, inducing enhanced IL-5 release and inhibiting macrophage 
adherence49•5o. T-cell cAMP increases on stimulation by VIP, but proliferation is 
inhibited"·51. However, reactivity of granuloma B-cells and macrophages is not 
affected"'''. 
Conflicting results emerge from studies in IBD patients. SP content of inflamed 
colon is increased, but there is a substantial overlap with normal SP content52 .53 . 
24 
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SP receptor upgrading is observed in inflamed areas of IBD colon"'''. SP 
receptor expression in ulcerative colitis enteric nerves has been found to be 
normal" or increased". For VIP the observations are even more confusing. 
Whereas VIP concentration in plasma of patients with active IBD is increased59, 
colon VIP content is reported to be either decreased53•54•60 or increased,s.6!. There 
is no clear relation between VIP content and disease activity. 
Somatostatin 
SMS was fn'st extracted fi'om ovine hypothalamus as an inhibitor of growth 
hormone secretion6'. SMS is a peptide hormone. There are two biologically 
active forms, consisting of 14 or 28 amino acids respectively (FIGURE 2.1). 
FIGURE 2.1 Schematic amino acid composition of somatostatin and octreotide. Shaded areas 
are essential for receptor binding. 
Somatostatin-14 Somatostatiu-28 Octreotide 
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Five types of SMS receptors have been discovered, each with specific binding 
characteristics for SMS subtypes and different SMS analogues6s. SMS receptors 
are found in upper and lower parts of the normal digestive tract66. 
SMS is an inhibitor of several key fimctions in the body. SMS inhibits acid 
secretion, intestinal fluid absorption, intestinal and pancreas secretion. SMS has 
effects on splanchnic blood flow and gastric and intestinalmotility"6. SMS exerts 
its inhibitory effects by diminishing intracellular cAMP through G-protein 
activation (FIGURE 2.2). In addition, SMS impedes cellular influx of calcium. 
This impediment results from a direct effect on calcium channels and from 
increase of potassium conductance with subsequent cellular hyperpolarisation"'. 
Circulating native SMS has a short half-life time. Long acting analogues like the 
decapeptide octreotide have been developed69 and SMS analogues have been 
used to treat intractable dialThoea, bleeding £i'om oesophageal varices in portal 
hypertension, dumping syndrome and gastrointestinal fistulae7o.74 • Radioactive 
labelled SMS analogues serve as diagnostic tools in visualisation of 
gastrointestinal neuroendocrine tumours75 • 
Immunomodulatory effects of somatostatin 
Studics on the immunomodulatory effects ofSMS show several effects on T- and 
B-Iymphocytes and macrophages. SMS receptors exist in spleen, liver, thymus 
d . . I I I'd' II .. 12 1576 an gastrollltestma )'mp 101 tissue, as we as on vanGlIS Ilnmunocytes ' , . 
Innllunomodulating actions of SMS were discovered as result of its antagonising 
effects of proliferation ofrat lymphocytes, stimulated by hypothalamic extracts77 . 
SMS inhibits responsiveness, immunoglobulin synthesis and proliferation of 
lymphocytes and granulocytesI5.45.46.78-80. It reduces TNF release and cellular 
toxicity of stimulated rat peritoneal macrophagesJO•8I . Inhibitory effects depend 
on local SMS concentration. Several ill vitro studies show inhibition of 
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proliferation of lymphoid cells at low SMS concentrations and stimulation at 
high levels'6,77, In an experimental model of intestinal inflammation with 
Schistosoma mansoni, SMS as well as its analogue octreotide decrease T-cell 
interferon production significantly", 
Some studies report several immunostimulating effects by SMS, T-cell 
proliferation is seen, also at low SMS concentrations')'"', In rat peritoneal 
macrophages SMS stimulates c)10toxic reactivity, when given in low 
concentrations'!, T-cell activation in a hybridoma T-lymphocyte cell line, 
measured by I1-2 release, is stimulated by SMS in a dose-dependent wai', 
However, IL-2 receptor expression is inhibited by SMS in human intestinal 
lymphocytes 47,48, 
SMS controls inflammatory processes in ill vivo experimental models. A 
reduction of inflammatory infiltrate and a diminished TNFa production occurs 
when SMS analogues are applied to animals in which carrageen-induced skin 
inflammation is established85 , In this experiment intense SMS innnunostaining 
was seen on leukocytes at peri-inflammatory sites. SMS reduces inflammation in 
experimental artln'itis and ileal obstruction86,87, Similar beneficial effects on 
intestinal and colonic inflammation emerge from clinical observations in Crohn's 
disease and gold-induced enteritisS8,S9, SMS is able to reduce SP mediated 
inflannnation induced by intestinal infection with Trichinella spiralis90 and SP 
enhanced neutrophil chemotaxis'), 
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FIGURE 2.2 Main cellular effects of somatostatin. Somatostatin receptors (SST) are cell 
membrane bound. After binding somatostatin (StvIS) G-proteins (0) are activated, through 
which adenylcyclase is inhibited (dark arrow), and calcium influx into the cell is hampered. 
Potassium channels are opened, and potassium influx increases. Decreased activity of 
adenylcyclasc leads to lower cyclic AMP (cAMP) levels, which also lowers intracellular 
calcium concentration. In smooth muscle cells relaxation is induced through this pathway. SMS 
also activates G-protein independent enzymes, like tyrosine phosphatase (Tyr Ph). 
After: Law SF, Woulfe D, Reisine T. Somatostatin receptor activation of cellular effects. Cell!Jar Signalling 1995;7:1-8 
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Somatostatin in IBD 
No systematic in vivo or ill vitro studies on effects of SMS in lED are available 
at present. Support for SMS induced inllnunomodulation in IBD is indirect and 
derived I1"Dln morphological and biochemical analyses of intestinal tissue and 
blood specimens Ii-DIn IBD patients. From several studies a correlation between 
SMS activity and presence and intestinal inflammation emerges. 
When measured in serum total body SMS release shows a circadian rhytlun91,,,. 
In active ulcerative colitis a higher 24-hour amplitude, higher average serum 
levels and a longer meal-stimulated peak level are observed"·93. As the serum 
concentration is only a faint mirror of the mucosal events, the impact of 
increased secretion of S"NIS is obscure. Same response pattems are seen in 
patients with duodenal ulcer or ilTitable bowel syndrome93 . 
SMS eontaining cells and submucosal ganglion cells in surgical specimen from 
IBD patients can be visualised by inllnunohistochemical staining and quantified 
by counting the SMS containing cells per mm. Mucosal SMS content can be 
assessed by radioimmunoassay of homogenised biopsy specimen. In normal 
colon mucosa, SMS containing endocrine cells show the highest density in the 
distal pm1s. In active IBD this distinct difference disappears. Studies prior to the 
discovery of SMS showed a decrease of neuroendoerine enteroclu'omaffm cells 
in diseased rectum of ulcerative colitis patients94 ,95. In ulcerative colitis there is 
an actual decrease in SMS containing cells, especially in the distal part of the 
colon96•99. Although these changes may be secondary to inflammatory damage to 
mucosal SMS containing cells, this is refuted by the fact that other I~lllcosal 
neuropeptides like SP show inereased levels in these cases98. SMS containing 
submucosal ganglion cells are evenly distributed along the colon in normals and 
IBD patients, but the number of these cells is decreased in IBD97. In colon 
epithelial cell cultures ii-DIn patients with active ulcerative colitis, decreased SMS 
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generation is observed. This loss of SMS production cOlTelates with disease 
activitylOO 
In Crohn's disease the loss of SMS containing colonic cells is less evident. A 
tendency towards decrease of SMS positive cells with increasing disease activity 
has been reported97. No difference of SMS content is seen in mucosa or normal 
ileum and terminal ileitis98. Mucosal biopsies from inflamed jejunum in Crohn's 
disease show normal levels of SMS, but soluble SMS is increasedlOl . This may 
reflect instability of SMS storage granules due to inflannllation. 
Several arguments for SMS involvement in mucosal inflammation emerge fi'OI11 
scintigraphic studies. An increased density of SMS receptors is found in areas of 
granulomatous inflammation like tuberculosis, sarcoidosis and Wegener's 
granulomatosusl02010-1. From SMS receptor Ineasurements in granulomas of 
murine intestinal Schistosoma mansoni infestation emerge the same results82. 
High-affinity SMS receptors are found in normal jejunum, ileum and colon lO5. 
Apali from presence in colon mucosa and nerve plexus, SMS receptors are found 
in the germinal centres of colonic lymph follicles. SMS receptors are seen in gut 
associated lymphatic tissue, like palatine tonsils, Peyer's patches, vermicular 
appendix and isolated lymphatic follicles in the colonl06 and SMS is isolated 
from nervous tissue in Peyer's patcheslO7. The precise fimction of SMS in this 
gut-associated lymphoid tissue has not yet been settled. High receptor density is 
seen in the luminal pUlis of secondary lymph follicles, but they are absent from 
the corona ofB-lymphoid cells. Lymphoid aggregates without a germinal centre 
do not show receptor activiti06. Interaction of SMS and lymphocytes fi'OI11 these 
germinal centres is reasonable. As these receptors have high affinity for SMS, a 
specific inullunomodulatory role of SMS is anticipated. Other indications for a 
direct influence of SMS on intestinal imlllunocytes can be derived from electron 
microscopic studies of the gut wall. SMS containing enteric nerve fibres are 
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present in a very high density near intestinal lymph follicles, coming close to 
follicular lymphocytes lO7 , 
Inhibitory effects of SMS on vascular cell proliferation have been described lOS, 
Expression of high affinity SMS receptors is seen in intramural veins of inflamed 
intestinal mucosa in IBD or peri-inflammatory veins in rheumatoid arthritis109,llO. 
No difference is seen in SMS receptor content of normal and inflamed tissue in 
mucosa, nerve plexus or lymphatic follicles. Precise cellular localisation of the 
SMS receptors is not possible from autoradiography, due to insufficient 
resolution of this visual technique. Histologically these receptor positive veins 
are normal, but the SUlTOllllding tissue often is infiltrated by leukocytes and 
receptor positivity is correlated with IBD activity109. However, expression of 
SMS receptors in vessel walls could be a non-specific response to inflammation 
as this phenomenon is also seen in peritumoral tissues in resected SMS receptor 
. I I . d I I' . 111 112 negatIve co on ac enocarcmorna an ot ler rna 19nancles ' . 
In animal experimental models of inflanmlatory bowel disease there are several 
suggestions of a role of S"NlS in the inflammatory mucosal responses. In murine 
experimental colitis SMS prevents mucosal damage effectively, especially when 
given before the introduction of the toxin 113. Parallel to decrease of mucosal 
lesions a decrease of inflammatory mediators such as leukotriene B4 and platelet 
activating factor is seen. 
hlterleukin-2 receptor expression and DNA synthesis in intestinal lamina propria 
lymphocytes (LPL) is reduced by SMS44•47,48. Proliferation of Peyer's patch 
derived lymphocytes is inhibited by SMS. Inhibitory effects of SMS on 
lymphocytic proliferation are more pronounced in intestinal derived T-cells than 
in spleen lymphocytes ll4 . Affinity of lamina propria lymphocytes for SMS-
binding was found to be 1000 times higher than peripheral blood lymphocytes in 
one stud/so 
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However, conflicting results emerge from a study in which effects on human 
peripheral blood lymphocytes and intestinal LPL were compared. The effects of 
SMS on intestinal LPL were minimal. Although both lymphoid cells expressed 
high affinity SMS receptors, intestinal lymphoid proliferation was poorly 
inhibited by SMS. Immunoglobulin synthesis was affected in a dose-related way 
in both peripheral and intestinal lymphocytes'". The fact that these results run 
counter to earlier repotied data, may be due to species differences and the lack of 
SMS receptor subtyping. 
Intestinal granulomas induced by Schistosoma mallsolli are smaller in presence 
of SMS. Their output of IFNy and innnunogiobulin is diminished by SMS. As 
these same granulomas are also capable of producing SMS, this suggests a local 
immunoregulatory role for SMSI9.82.115. Tills is supported by the interesting 
observation that intra-epithelial lymphoid cells can stimulate isolated intestinal 
epithelium to produce SMS I16. 
Conclusion 
From morphological studies it is clear that neuropeptides are probably involved 
in the control of the intestinal immune system. Immune stimulatory and 
inhibitory effects emerge fi'om various in vitro studies and from sparse in vivo 
experiments. S1\1S has been shown to inhibit inullulloiogical processes at variolls 
sites following different stimuli. As SMS receptors show a high density in the 
gastrointestinal associated lymphoid tissue and in inflammatory granulomas in 
murine .Schistosoma mallsolli infestation, it seems likely that SMS and its 
receptors playa role in immunological events of the digestive tract. Mucosal 
SMS content is reduced in active IBD. The beneficial effects of SMS and SMS 
analogues on experimental inflammation of skin, joints and intestine and the few 
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reports on open studies in patients with lED suggest that SMS and SMS 
analogues could possibly be beneficial in lED and should stimulate fiuiher 
clinical studies. 
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SOMATOSTATIN PREVENTS MUCOSAL INFLAMMATION IN 
ACUTE DEXTRAN SULPHATE SODIUM-INDUCED COLITIS 
J.D.van Bergeijk, M.E.van Meeteren, A.P.M.van Dijk, C.J.A.M.Tak, 
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Abstract 
Somatostatin (SMS) is a potent immune inhibitory neuropeptide, able to reduce 
acetic acid-induced acute colon damage in rats. We studied the proposed anti-
inflammatory effect of somatostatin in acute dextran sulphate sodium (OSS)-
induced colitis. This model is characterised by neutrophil infiltration of colon 
mucosal and submucosal regions. 
Osmotic pumps containing saline or somatostatin were subcutaneously inserted 
in 4 groups of BALB/c mice. Somatostatin was released at 120 ~lg per day (6 
f'g/g mouse/day). At day 5 of the study two groups (one saline, one somatostatin) 
were exposed to DSS 10% (w/v) in their drinking water. Two days afterwards all 
mice were sacrificed and small bowel, colon, thymus and spleen were removed 
for cytokine analysis. Colon and ileum specimens were examined 
microscopically. 
DSS induced a mild, superficial colitis. Somatostatin effectively reduced 
intestinal neutrophil infiltration, without changing macroscopic disease activity. 
Interleukin (IL)-6 levels were decreased in DSS treated animals, il1'espective of 
somatostatin admiuistration. A role of macrophages in this colitis model is 
suggested. Other cytokines (IL-I~, IL-2, IL-IO, interferon y) in colon, thymus 
and spleen specimens were equal in all four groups, indicating that intestinal or 
peripheral blood lymphocytes are not involved in the early phase ofDSS-induced 
colitis, nor in the anti-inflammatory effect of somatostatin. 
We conclude that somatostatin prevents DSS-induced colitis effectively, by an as 
yet undefined mechanism. 
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Introduction 
Several neuropeptides are morphologically and functionally related to the 
intestinal inllllllle system. Whereas most neuropeptides have pro-inflannnatory 
propelties, somatostatin (somatotropin release inhibiting factor, SMS) exerts 
mainly inlllUne inhibitory effects I. SMS reduces intestinal lymphocyte 
immunoglobulin synthesis and proliferation, and also peritoneal macrophage 
activity'·6. Canageenin-induced inflaillination in rats is attenuated by SMS, 
irrespective of local or systemic administration7. In human disease beneficial 
effects of SMS ill rheumatoid artlu·itis and in thymoma have been repOlted'·'. The 
anti-inflammatory role of SMS is disputed by failing to improve E.eoli 
lipopolysaccharide-induced inflammation in mice iO• Octreotide is a long-acting, 
synthetic SMS analogue. When given prior to induction of pancreatitis octreotide 
improves mOitality, yet without changing the inflammatory response 
histologically". Moreover, inlllUne inhibitory effects may aggravate 
inflanllnation as T cell activity in response to parasite infestation is restrained by 
SMS 12. The SMS analogue octreotide prevents acute mucosal damage by acetic 
acid, that was accompanied by a reduction of mucosal SMS content l3 . Acetic 
acid induces colitis by epithelial damage. Dextran sulphate sodium (DSS)-
induced colitis in rodents is a very reproducible experimental model of colitis 
that has several similarities with human inflammatory bowel disease. DSS 
changes intestinal macrophage activity as well as intestinal microfloraI4•15• When 
administered repetitively, DSS causes a cln'onic colitis, which is not seen in 
acetic acid-induced colitis. Although T-Iymphocytes are activated during DSS 
exposure, colitis may be induced in T cell depleted animals 16. In our colitis 
model we investigated the potential beneficial effect of SMS, continuously 
released from a subcutaneous pump in mice. We expected a reduction of mucosal 
leukocyte infiltration and intestinal proinflannl1atory cytokines. 
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Methods 
All studies were approved by the Erasmus University Ethical Committee for 
Animal Experiments. Osmotic pumps (Alzet, Germany, type 1007D) were 
implanted during ether anaesthesia in the nuchal subcutis in four groups of S 
female young adult BALBlc mice. Pumps were filled with either saline (groups 
A and B) or SMS-14 (groups C and D). SMS-14 (Somatofalk®) was obtained 
fi·om Tramedico, Weesp, the Netherlands. The pumps released SMS in a 
continuous daily dose of 120 Ilg. At day five after pump implantation groups B 
and D were exposed to DSS 10 % (w/v, MW > 500 kDa, Phannacia, Sweden) in 
drinking water, to which they had free access. After obtaining a macroscopic 
disease activity index (see below) at day seven all animals were killed by cervical 
dislocation after an overnight fast. The small bowel, colon, thymus and spleen 
were removed inunediately. After careful cleansing, the colon was divided into 
tln·ee equal parts. From each patt and fi·om the terminal ileum specimens were 
fixated in formaldehyde, processed and embedded in paraffm wax for 
histological evaluation. Sections were stained with a standard haematoxylin and 
eosin staining. After measuring tissue specimen weights the rest of the colon, 
approximately 2 cm of terminal ileum, thymus and spleen were placed in a 
standard Krebs' buffer (PH 7.4) containing in nunollL: lIS NaC!, 4.7 KCl, 2.5 
CaCl,·2H,O, 1.2 MgSO.·7H,O, 25 NaHC03, 1.2 KH,P04 and S.2 D-glucose. 
After hOl1logenising (Ultra-TUlTax, Polytron, Switzerland) specimens were 
cenh·ifhged during 10 min. at 2800 x g, 4°C. The supernatants were kept at -20 
°C until analysis. Cytokine ELISA's were performed using conmlercial antibody 
pairs (Biosource, Belgium) for specific mouse interleukin (IL)-IP, lL-2, IL-6, IL-
10, and interferon (IFN)-y. ELISA's were performed according to the 
manufacturer's instructions. 
All experiments and analyses were performed in a blinded maImer. Cytokine 
values are given in pg per mg wet tissue (mean ± standard error). 
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Macroscopic evaluation included body weight, stool consistency, rectal bleeding, 
appearance of hair, liveliness, colon colour and distension, and serosal thickening 
(maximulll total score 10 points). Colon and ileum inflanmlation was scored 
histologically according to Okayasu: 0 = no inflammation; 1 = focal neutrophil 
infiltration; 2 = diffuse infiltration, crypt abscesses, goblet depletion; 3 = 
ulceration (15). Histology scores of proximal, middle and distal colon segments 
were added and the average of all scores was taken as the final histology score. 
Statistical analysis was performed by an unpaired Student's t-test for cytokine 
results and histological scores were compared using a Wilcoxon rank sum test for 
independent samples (statistical significance: p::: 0.05). 
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FIGURE 3.1 Histology according to Okayasu criteria (see text and ref. 15), mean ± SEM. 
A = control; B = DSS; C = SMS; D = SMS I DSS. 
B statistically different from A, C and D (* P < 0,0 l) 
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Results 
Macroscopylhistology 
All mice were sacrificed at day 7 between 9 and 10.00 alll. Macroscopic scores 
were significantly higher (I' < 0.001) in DSS treated groups receiving saline (2.5 
± 004) or SMS (2.5 ± 0.4) compared to controls (0.1 ± 0) and SMS alone (0.1 ± 
0). Group B, not receiving SMS, had developed a mild colitis, involving mucosal 
and submucosal layers (score 3.4 ± 0.4) significantly different from controls (1.8 
± 004) and SMS treated groups (2.0 ± 0.3 and 1.8 ± 0.4 respectively). SMS 
treated groups did not differ from controls (FIGURE 3.1). All ileal specimens 
were normal (score = 0). 
Cololl 
IL-6 levels were significantly lower in DSS-receiving groups irrespective of 
SMS administration (FIGURE 3.2). Other cytokine values are depicted in 
TABLE 3.1. IL-IP levels in SMSIDSS treated animals were lower than in all 
other groups, though statistical significance was not reached. Also IL-2 levels in 
DSS and SMSIDSS groups were lower than controls (NS). IL-IO concentration 
in DSS and SMSfDSS receiving mice was lower than controls (NS). IFN-y was 
barely detectable in all colon specimens. 
TABLE 3.1 Cytokines in colon homogenates; only statistical significant difference in JL-6 
levels. Mean ± standard error (pglmg tissue) 
control DSS SMS SMStDSS 
IL-1P 120 ± 38 107 ± 49 180±60 60± 23 
1L-2 I IO± 19 53±28 138± II 83± 21 
IL-IO 165±41 93±17 153±43 117±27 
IL-6 315±68 112 ± 24* 357 ± 90 90 ± 23* 
IFNy 4±2 3±2 6±3 7±3 
• p < 0.05 compared to control 
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FIGURE 3.2 Interleukin-6 (IL-6) in pg per mg colon tissne (see table I), mean ± SEM. 
A ~ control; B ~ DSS; C ~ SMS; D ~ SMS I DSS. Levels equal in Band D, but in both 
groups statistically different from A and C (* P < 0.05). 
Thymus and spleell 
Although IL-lP, IL-2, IL-6 and IL-lO levels in SMS treated animals were higher 
than in the other groups, no statistical significance was reached (TABLE 3.2). 
IFNy was hardly detectable (data not shown). No statistical significant 
differences in cytokine levels were found in spleen tissue (TABLE 3.3). SMS 
groups tended to lower IL-2 levels (NS). IFNy was not detectable. 
TABLE 3.2 Cytokines in total thymus homogenates; no statistical differences 
Mean ± standard error {pglmg tissue}. 1\11) = not detectable. 
control DSS SMS SMSiDSS 
IL-IP 13 ±2 20± 5 31 ± 13 23±4 
IL-2 10 ± 2 17±2 32± 20 15±3 
IL-6 55 ± 11 58 ± 19 178 ± 126 59±21 
IL-IO 25 ± 5 29±8 55±27 37 ±9 
IFN'l ND ND ND ND 
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TABLE 3.3 Cytokines in total spleen homogenates; 110 statistical differences 
Mean ± standard error (pglmg tissue). ND = not detectable. 
coutrol DSS SMS SMS/DSS 
IL-IP 6±1 8±2 5±2 9±3 
IL-2 4±1 5±2 3± I 5±1 
IL-6 IO±4 5±2 8 ± I 5±3 
IL-1O 8±3 5±2 6±1 6±2 
IFNr ND ND ND ND 
Discussion 
High molecular DSS is able to induce an acute, superficial colitis in mice within 
two days of exposure. DSS induces neutrophil infiltration of mucosal and 
submucosal areas. In tlus early phase of inflanmlation, DSS disables mucosal 
macrophage phagocytose function after cellular uptake by these ceIls"·I7. This 
enables intraluminal anaerobes to invade the intestinal mucosa and induce 
colitisl4. As inflammation lasts after discontinuing DSS, other mechanisms must 
also be involved. Direct toxicity to intestinal epithelial cells and interference with 
leukocyte adhesion is suggested". Although DSS influences activity ofT- and B-
lymphocytes ill vitro!9-'l, lymphocytes do not seem essential for the induction of 
DSS colitis"·2l. On the other hand, T lymphocyte derived cytokines are found in 
mouse colon mucosa by immunohistochemic techniques in chronic DSS-induced 
colitis". In our study the mucosal JL-6 levels were lower in DSS treated animals. 
As IL-6 is a mainly macrophage derived cytokine, this drop ofIL-6 content may 
reflect diminished macrophage activity. Olson et al. found unchanged plasma JL-
6 concentrations in mice after two days of DSS exposure, but mucosal JL-6 
content was not measured25 . 
Marked amounts of colon neutrophils were found in DSS-induced colitis. SMS 
prevented this neutrophil infiltration effectively. The influence of SMS on 
intestinal leukocytes may be more distinct in the early phase of their activatiOI{ 
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SMS did not influence macroscopic disease activity, as the macroscopy score in 
both DSS receiving groups did not differ. In this stage SMS did not reduce 
diarrhoea or bloodloss. In this early DSS-induced inflammatory state, although 
statistically different fi-Dln controls, animals did not have severe disease (mean 
macroscopy score 2.5 on a 10 point scale). In acetic acid induced colitis however, 
octreotide pre-treatment diminished diarrhoea, parallel to a reduction of mucosal 
damageD. In our study SMS prevented inflanmlation when administered 5 days 
before exposure to DSS. This is in line with the results of the study of Eliakim et 
aI., in which a marked inhibition of acetic acid-induced inflallllnation occurred in 
rats that were pre-treated with octreotideD. 
The mode of action of mucosa protection by SMS to DSS is still speculative. A 
direct inhibition of SMS on neutrophil influx may be anticipated, but such an 
effect is not supported by other studies. Octreotide did not influence endotoxin-
induced impairment of leukocyte migration lO , and high doses SMS may even 
stimulate leukocyte movement in vitro'·,27. An inhibition of lymphocyte activity 
as stated before'-5 is not likely. IL-l p, IL-2, IL-IO and IFNy were similar in all 
study groups, suggesting that lymphocytes be not involved in this phase of DSS-
induced colitis as reported by others22. Influence from peripheral lymphocytes is 
not very feasible, as DSS did not affect the cytokine levels of spleen and thymus 
homogenates. SMS may hamper bacterial invasion of the mucosa in the early 
phase of DSS-exposure. However, in a study of bacterial translocation in mice, 
octreotide reduced the beneficial effects of a high fibre diet on the bacterial 
. . 28 
1111gl'atlOll . 
Colon macrophages phagocytose DSS, which disturbs their function in the early 
phase of DSS-induced colitisI4,I5,17, probably reflected by the low colon IL-6 
levels we found. As a marked reduction of macrophage phagoc)~otic response by 
SMS is reported·, this may result in diminished DSS uptake by macrophages. 
This is not sUPPOlied by the low IL-6 levels in SMSIDSS treated animals, 
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suggesting that DSS still has a chance to affect macrophage activity. However, 
we did not study the chemoattractive activity of macrophages, which may be 
diminished by SMS29 • 
In both acetic acid- and DSS-induced colitis the enteric nervous system is 
involved in the protection against these toxins30,31, Impaired neuron function in 
these models promotes mucosal neutrophil influx. DSS induces nerve cell 
hyperplasia in the distal colon, with increase of pro-inflammatory neuropeptides 
like substance P and neuropeptide y32. As SMS is a well-known substance P 
antagonist and inhibits several immunological effects of this proinflanmlatory 
neuropeptide33•J4 , it seems likely that this may diminish DSS-induced colon 
damage. 
In conclusion, in our animal model, SMS prevented DSS-induced colitis 
effectively. Characteristically, it affected DSS-induced neutrophil infiltration in 
colon mucosa and submucosa. This anti-inflatmnatory effect of SMS still has to 
be settled. Lymphocyte inhibition seems not involved. Probably SMS inhibits 
macrophage chemoattractive activity or SMS interferes with proinflammatory 
neuropeptides or protects the enteric nerve system. 
l7lts research was sponsored by Tramedico BV, Weesp, The Netherlands. 
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Abstract 
Acute colitis induced by acetic acid in rats is attenuated by the long-acting 
somatostatin (SMS) analogue octreotide. We studied the potential beneficial 
effect of SMS on non-acute experimental colitis. BALBlc mice received either 
saline, SMS-14 (36 or 120 f'g daily) or octreotide (3 f'g daily) subcutaneously 
delivered by implant osmotic pumps. A non-acute colitis was induced by 
administration of dextran sulphate sodium (DSS) 10 % in drinking water during 
7 days. DSS evoked a mild, superficial pancolitis, most characterised by mucosal 
ulceration and submucosal influx of neutrophils. Neither SMS-14 nor octreotide 
reduced the mucosal inflammatory score or macroscopical disease activity, 
although the suppressed intestinal levels of interleukin-l p (IL-I P), IL-6 and IL-
10 during DSS were fmiher reduced by both SMS and octreotide. A slight 
increase of neutrophil influx was seen during SMS administration in animals not 
exposed to DSS. In conclusion, SMS or its long-acting analogue did not reduce 
intestinal inflammation in non-acute DSS induced colitis. However, based on the 
cytokine profile observed, SMS-14 and octreotide may fhrther reduce the 
intestinal macrophage and TH, lymphocyte activity, which has been suppressed 
by DSS. 
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Introduction 
Neuropeptides play key roles in intestinal inflatllillation I. One of the most active 
inhibitory neuropeptides is somatostatin (SMS), which has dose dependent 
inhibitory effects on lymphocyte proliferation and cytokh,e production, 
innnunogiobulin synthesis atld macrophage function'. It stimulates the 
development and immunologic activity of intestinal granulomas in murine 
Schistosomiasis monsoni infection3.4. Mucosal depletion of SMS is observed in 
inflammatory bowel disease"'. In contrast, blood SMS levels in active IBD are 
elevated, suggesting a defensive role in intestinalmncosal injury"lO, Octreotide, a 
long-acting SMS analogue, is able to reduce epithelial damage in an animal 
model of acute experimental colitis", No data are available on the effects of 
somatostatin or its analogues on chronic colitis. 
When laboratory animals are exposed to dextran sulphate sodium (DSS) in their 
drinking water, a mild colitis develops. Although one of the characteristic events 
evoked by DSS is an enhanced T-cell response", colitis is induced iuespective of 
the presence or absence of lymphocytes l3 ,,,. DSS-induced colitis is a highly 
reproducible model of intestinal inflammation, mimicking celtain aspects of 
human inflammatory bowel disease". In the acute phase it is characterized by a 
predominantly left-sided, acute colitis, which is not contiguousI6,17. By one week 
of DSS exposure, a mild subacute colitis develops, which responds to several 
immune-modulating agents 1S.20, Certainly pro-inflallllllatOlY neuropeptides 
(substance P, neuropeptide Y) are involved in DSS-induced colitis". The 
relevance of inhibitory neuropeptides like SMS in this model has not been 
studied. 
We aimed to determine the role of SMS in DSS-induced subacute intestinal 
inflanullation in mice, focussing on intestinal leukocyte infiltration and cytokine 
content. Pro- as well as anti-inflammatory cytokines were examined in this study. 
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Based on the described immune inhibitory effects, we anticipated a beneficial 
effect of SMS administration on intestinal mucosal damage induced by DSS. 
Methods 
Experimental protocol 
All experiments were approved by the Laboratory Animal Ethics Committee of 
the Erasmus University. FOlty young female BALBlc mice (20 to 22 g) were 
randomly allocated to 8 groups (A to H). All mice had osmotic PUlllPS (Alzet, 
Germany) inselted subcutaneously in the upper region of the back under ether 
anaesthesia. Osmotic pumps were filled with saline, SMS-14 or octreotide. 
Groups A and B received normal saline. The pumps in groups C, D, E and F 
were filled with SMS acetate, containing SMS-14 (Somatofalk®, Tramedico, 
Weesp, the Netherlands). These pumps continuously released SMS-14 
subcutaneously during 7 days (groups C and D 36 >Jg, and groups E and F 120 >Jg 
daily). Groups G and H received octreotide 3 >Jg daily (Sandostatine®, Novartis, 
Basle, Switzerland). Immediately after insertion of the pumps animals in groups 
B, D, F and H were exposed to DSS 10% in their drinking water during 7 clays. 
Control groups were allowed to drink normal water. All animals had fi-ee access 
to drinking water and normal food. After to an overnight fast, animals were killed 
by cervical dislocation 7 days after implantation of the osmotic pumps. All 
operations and sacrificing took place between 9 and II am. 
Macl'oscoPY 
Severity of inflammation was documented macroscopically, based on changes of 
bodyweight and general appearance (hair, liveliness), stools and rectal bleeding, 
and color, distension and serosal appearance of the colon directly after opening 
of the abdomen. A maximum macroscopic score of 10 points was allocated, 
according to the following: as adolescent mice gain at least 5% bodyweight pel' 
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week, change of body weight of more than 5% was scored 0,0-5% gain = I, loss 
of bodyweight = 2. Hair was normal (0) or dull (I); mice were lively (0) or 
apathetic (I). Stools were normal (0), semiliquid (I) or liquid (2). Rectal bleeding 
was given I point. Colon colour was normal (0) or red (I); distention was absent 
(0) or remarkable (I). The serosal aspect was normal (0) or thickened (1). 
intestinal specimens 
Inullediately after sacrificing, the colon and small bowel were removed. Faecal 
contents were carefully extruded. Fragments of terminal ileum, and proxinlal, 
middle and distal colon were cut to a standardized length alongside a measlll'ing 
rod. Specimens for histology were placed immediately in formaldehyde. For 
cytokine analysis fragments were kept in Krebs buffer after weighing. 
Histological examination 
Histological sections fi'om ileum, and proximal, middle and distal parts of the 
colon were stained (haematoxylin and eosin) and scored to extent of 
inflammation (O=none, l=mild, 2=mocierate, 3=severe), damage (O=none, 
I =superficial, 2=involving m.mucosae, 3=transmlll'al), and regeneration (3=none, 
2=focal, I=multifocal, O=complete)Il. Assessments were made by a blinded 
committee. Scores from proximal, middle and distal colon parts were added to 
obtain a total histology score per animal. 
Cytokille allalysis 
Tissue specimens were fi'agmented dlll'ing 10 seconds in Krebs buffer (Ultra-
TlIl'rax, Poly ton, Switzerland) and centrifhged (lO.OOOxg, 10 min., 4°C). The 
supernatant was stored at -80°C for cytokine assay. Levels of interleukin-I beta 
(IL-I P), IL-6, IL-I 0 and interferon gamma (IFNy) were measlll'ed by ELISA kits 
for assay of mouse cytokines (Biosolll'ce, Belgium)_ Levels are expressed as 
cytokine per tissue weight (pg/mg). 
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Analysis 
Descriptive analysis was performed conceming macroscopic changes. Cytokine 
values were expressed as mean ± standard eITor. Results were analysed using a 
Wilcoxon two-sided rank sum test for small samples (macroscopy/microscopy) 
or an unpaired t-test (cytokine levels). P-values under 0.05 were considered 
statistically significant. 
Results 
Macroscopy 
All DSS treated animals developed colitis and revealed a significantly higher 
macroscopy score than controls (6.2 ± 1.2 versus 0.4 ± 0.2, p < 0.01). 
Macroscopy scores in groups C, E and G (,non-inflamed') did not differ fi'om 
controls (0.8 ± 0.6, 0.8 ± 0.4, and 0 ± 0, NS compared to A). Neither SMS nor 
octreotide affected macroscopy scores significantly in the colitis groups D, F and 
H (4.8 ± 1.6, 5.8 ± 0.9 and 7.0 ± 1.4, NS compared to B). 
Histology 
No inflammation was seen in the ileum. A mild pancolitis was induced by DSS. 
Mucosal infiltration of polymorphonuclear neutrophils (PMN) was the most 
remarkable finding. Histology scores fi'OJn proximal and distal colon pmts in 
animals exposed to DSS did not differ. Scores in groups B (7.2 ± 0.5), D (8.8 ± 
0.8), F (6.8 ± 0.6) and H (8.6 ± 1.2) were significantly higher than group A (3.0 ± 
0.3, p ~ 0.05). Scores from group E (3.6 ± 1.7) and G (4.2 ± 0.8) were higher 
than controls, but these differences were not statistically different. In group C 
inflammatory score was high (5.2 ± 0.8), merely due to PMN infiltration. 
Mucosal damage was not obviously present in group C as the total microscopy 
score minus the score for PMN infiltration was 1.6 ± O.S points for group C, 
compared to 0.8 ± 0.2 points for controls (p > 0.05). 
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Cytokines 
IFNy was barely detectable in most samples (<: 0,4 pglmg). Statistical analysis 
was not possible, due to the abnormal distribution of data. IL-I ~ levels in groups 
B, C, D, F, G and H (15.5 ± 3.3, 19.3 ± 3.5,19.2 ± 7.3,5.9 ± \.7, 10.6 ± 1.8 and 
10.1 ± 5.4 pglmg) were significantly lower than in group A (27.4 ± 5.3 pglmg, p 
<: 0.05). Mucosal IL-I~ concentration in group E (27.5 ± 7.9 pglmg) was not 
different limll A (FIGURE 4.1a). In F the IL-I~ levels were significantly lower 
than in B (p < 0.001). IL-6 levels in groups B, D, F, G and H (21.3 ± 5.1, 21.4 ± 
5.2, 14.1 ± 4.1, 27.4 ± 2.8 and 12.1 ± 5.9 pglmg) were lower than in group A 
(54.5 ± 11.2 pglmg, p < 0.01, FIGURE 4.1b). IL-6 levels in C (45.6 ± 5.5) and E 
(51.7 ± 6.8 pg/mg) did not differ 1;-0111 A (p > 004). D, F, G and H did not 
significantly differ from B (p = 0.2). IL-IO concentration (FIGURE 4.lc) in 
group B (9.7 ± 3.8 pglmg) was lower than in A (20.9 ± 6.2 pglmg), but statistical 
significance was not reached (p = 0.17). IL-IO levels in D, F and H (6.7 ± I. 7, 
6.3 ± 2.4 and 6.1 ± 0.7 pglmg) were lower than in controls (p < 0.05). In groups 
C (16.2 ± 3.8 pglmg), E (22.8 ± 6.9 pglmg) and G (14,9 ± 4.9 pglmg) IL-IO 
levels did not significantly differ ft'om controls. 
Discussion 
In our study DSS induced a mild, superficial colitis in BALBlc mice, both left 
and right sided, rarely involving layers beyond the muscularis mucosae. The 
most characterising fmding was mucosal infiltration by neutrophils (PMN). 
Neither SMS nor octreotide attenuated DSS induced mucosal inflanllllation. 
Animals given low doses of SMS and octreotide on normal drinking water 
showed a marked mucosal infiltration by PMN, without mucosal damage. In 
these groups mucosal IL-l ~ content was reduced, perhaps reflecting a negative 
feedback on IL-l ~ by increased PMN influx. This increased PMN influx was 
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FIGURE 4.1 Cytokinc levels in colon mucosa in pglmg tissue weight. A = saline; B = 
salinelDSS; C ~ SiviS 36 ~tg; D ~ SiviS 36 pg/DSS; E ~ SMS 120 pg; F ~ SiI'IS 120 pg/DSS; G 
~ OCT 3 ~tg; H ~ OCT 3 pg/DSS (*p>0,05 vs A). 
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limited to the colon, as all ileal specimens were normal. As neutrophil migration 
into the intestinal mucosa is the prominent phenomenon in DSS-induced colitis, 
the meaning of this infiltration without mucosal damage is not clear. III vill'o 
leukocyte migration is stimulated by SMS by an as yet undefined mechanism22 ,2l, 
Several beneficial effects of SMS or SMS analogues on intestinal inflannnation 
of various aetiologies have been demonstrated"-27, In an acute model of 
experimental colitis induced by acetic acid octreotide in high dose attenuated 
mucosal inflammation and local cytokine and eicosanoid production II, The most 
distinct effect was seen when octreotide was administered the day before 
induction of acute colitis, As no follow-up studies on rate of mucosal 
regeneration were performed, no data are known on the possible beneficial 
effects of octreotide in the post-toxic period of acetic acid, The differences in 
results with acetic acid-induced colitis and our findings might be due to the use 
of different models or different species or both, Acetic acid induced colitis is an 
acute toxic model in which non-specific inflammation prevails15, DSS induced 
murine colitis is a model of acute as well as non-acute colitis 13,16,17, This model 
has been found suitable for studying involvement of mediators of mucosal 
inflammation and evaluation of antiinflammatory treatment18,20,28, DSS most 
likely acts as a direct mucosal toxin, as inflammation occurs irrespective of the 
presence of lymphocytes or other mucosal imlllunocytes IJ ,I4,29, However, in the 
non-acute DSS induced colitis intestinal macrophages, neutrophils and 
lymphocytes are involved IJ,I9,JO, Corticosteroids, cyclosporin A or anti-neutrophil 
serum attenuate DSS-evoked inflammatory changes 1S-20 , 
In chronic DSS induced colitis an enhanced THI response is observed, 'yhich is 
accompanied by increased intestinal IFNy contentJ1 , However, we were not able 
to detect IFNy in our intestinal specimen, perhaps due to the low concentrations 
observed after 7 days of DSS exposureJ1 , IL-4 levels are elevated and IL-5 
concentrations drop after 14 days of DSS exposureJ2, indicating differential 
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effects on TIl, activity. We found low mucosal IL-IO levels in DSS induced 
colitis compared to controls, what may be a direct or indirect effect of DSS on 
TIl, lymphocytes. SMS and octreotide did not abolish this effect, but even further 
reduced IL-IO concentrations. We observed a striking decrease ofIL-IP and IL-
6, after 7 days ofDSS administration. Tllis reduction was enhanced by SMS 120 
[1g and octreotide. In the DSS model of experimental colitis, reduction of IL-I P 
and IL-6 suggests a reduced activity of mucosal macrophages as well as nl, 
lymphocytes. The reduction of pro-inflammatory cytokines may reflect a phase 
of mucosal regeneration in this stage of subacute colitis after one week of DSS 
exposure. The study period was probably too short to detect beneficial effects of 
SMS on the rate of post -exposure healing. Moreover, SMS has been reported to 
delay intestinal mucosal regeneration33. The dual effect of different doses SMS 
may reflect different local mucosal concentrations and subsequent receptor 
activation. This effect is not influenced by the ShOlt half time of this instable 
compound, considering similar results obtained by octreotide. 
In conclusion, in mice SMS or octreotide administered subcutaneously during 
one week of oral DSS exposure did not attenuate colon mucosal inflammation. 
Low levels of mucosal IL-I P following DSS administration, were further 
decreased during high doses SMS. During administration of SMS a marked 
influx of PMN in colonic but not ileal mucosa was observed, also in animals not 
receiving DSS. These animals showed lower concentrations of mucosal IL-I P 
than control animals. The meaning of this promotive role of SMS on neutrophil 
migration still has to be settled. SMS and octreotide amplified the DSS-induced 
decline of intestinal levels of ILlP, IL6 and ILlO, suggesting further inhibition 
of macrophages and TIl, lymphocytes. 
This research has been sponsored by Tramedico, Weesp, The Netherlands 
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CHAPTER 5 
RESPONSE TO CARBACHOL AND SALBUTAMOL IN 
DEXTRAN SULPHATE SODIUM-INDUCED COLITIS IS 
MODULATED BY SOMATOSTATIN 
lD.van Bergeijk, F.J.Zijlstra 
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Abstract 
The effects of somatostatin (SMS) and its analogue octreotide (OCT) were 
studied on contractile activity of mouse colonic smooth muscle in experimental 
colitis, induced by addition of dextran sulphate sodium (DSS) 10 % (w/v) to the 
drinking lVater. 
BALB/c mice received subcutaneous osmotic pumps delivering either normal 
saline, somatostatin 6 Ilg or octreotide O.IS fIg pel' g body weight pel' day. DSS 
10% (w/v) was given to half the mice for 7 days immediately after implantation 
of the osmotic pumps. Mice were killed at day 8 and pmts of the transverse colon 
were used to study isotonic contraction in an organ bath. 
DSS 10% induced a mild, superficial colitis, leaving the muscular layer 
uninvolved. SMS or OCT did not affect the degree of in flann nation. 
Concentration-response curves were obtained by adding carbachol (CARn) in 
increasing concentrations (10.8 - 10'] M). After maximal contraction with 10'] M 
CARn, increasing concentrations of salbutamol (SALB) were administered (lO·g 
- 10'] M). From both log dose-response curves a half-maximum concentration 
lVas calculated (ECSOCARB and ECSOSALB). 
Both ECSOCARB and ECSOSALB increased significantly in DSS-induced colitis, 
suggesting a decreased sensitivity to both agents. After SMS and OCT treatment 
ECSOCARB retumed to the control value, whereas ECSOSALB was further increased. 
Maximum SALB-induced smooth muscle relaxation lVas decreased after DSS 
exposure. 
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Introduction 
Intestinal inflannl1ation is accompanied by altered gut smooth muscle function 
and motility, manifested clinically as diarrhoea and a decreased reservoir 
function, Diarrhoea may be due to an increase of the number of colonic giant 
migration conh'actions, rather than increased colon contractilityl, Inflanl1l1ation 
decreases maximum smooth muscle cell contractility and force after stimulation 
with muscarinic agonists, without affecting the half-maximum dose (EC50)'-', 
Less is kuown about the influence of intestinal inflammation on smooth muscle 
relaxation, Adrenergic stimuli are one of the mediators of colon smooth muscle 
re[axation'-', with different effects in circular (both u- and p-adrenergic) and 
longitudinal (p-adrenergic) muscle cells', 
Enteric nerve function and the intestinal content of neuropeptides are changed in 
inflannl1atory bowel diseases,9, Neuropeptides like substance P (SP), vasoactive 
intestinal polypeptide (VIP) and somatostatin (somatotropin release inhibiting 
factor, SMS) are important mediators in the nervous control of intestinal motility 
and mucosal inflanl1l1ation lO, In general, SP and VIP are thought to promote 
smooth muscle cell contractilitylO, SMS is an important inhibitory neuropeptide, 
The effects of SMS on muscle activity are complex, In healthy subjects it 
diminishes colon transit time by an as yet unknown l1lechanism lI ,l', Interference 
of SMS with agonists and antagonists affecting contraction has been shown in ill 
vitro studies, Preincubation of smooth muscle cells with SMS attenuates 
carbachol (CARE)-induced contraction IJ , In bronchial smooth muscle cells SMS 
reduces the p-adrenergic-induced re[axation14, In the rat colon a dose-dependent 
contractile effect of SMS and its analogues is observed, with a marked 
desensitisation if the dl1lg is re-administered after five minutesl', However, there 
are species differences, In dog colon muscular strips SMS inhibits spontaneous 
contraction16 and in guinea pig colon a slight contractile effect is seen in the 
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circular muscles and an inhibition of carbachol-induced contraction in both 
circular and longitudinal muscular cells lJ • 
SMS and its analogues have anti-inflammatory effects 17 and beneficial effects on 
bowel movements and diarrhoea in active Crolm's disease have been 
reported!8.!,. However, it is not clear whether the beneficial effccts are due to 
modulation of the gut immune system or direct inhibition of smooth muscle 
activity. 
Dextran sulphate sodium (DSS)-induced colitis is an animal inflammatory model 
characterised by a mild, superficial colonic inflatmnation, leaving the muscular 
layers intact20 • In earlier studies in this colitis model in mice we found a marked 
loss of maximal contraction on carbachol stimulation and a diminished 
nitroprusside-induced relaxation in the inflamed colon, especially in the 
transverse part2!. We studied the effects of subcutaneous administration of SMS 
and its long-acting analogue octreotide on in vitro transverse colon smooth 
muscle contraction and relaxation in mice with dextran sulphate sodium (DSS)-
induced colitis. Octreotide has a plasma half-life of 20 minutes; SMS has a very 
short plasma half-life after single subcutaneous administration (about I 
minute)22. We gave both drugs through subcutaneous osmotic pumps, making a 
continuous delivery possible. 
Methods 
The University Experimental Animal Ethic Committee approved all experiments. 
The experiments were all performed in a blinded fashion. 
Six groups of female young adult BALBlc mice (20 - 22 g) were kept under 
standardised laboratory conditions. In all mice osmotic pumps (model 1007 D, 
0.5 ilL per hour, Alzet, Germany) were implanted subcutaneously in the 
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suprascapular region. Pumps were filled with either normal saline, or SMS 
(SMS-14, Somatofalk®, Tramedico, Weesp, The Netherlands) or the long acting 
SMS analogue octreotide (OCT, Sandostatin®, Novat1is, Basle, Switzerland). 
They continuously released saline, 6 f.lg SMS or 0.15 f.lg OCT per g body weight 
per day (dose difference based on different half-lives). Thereafter, mice were 
randomly allocated to either normal drinking water or drinking water containing 
10 % (weight/volume) dextran sulphate sodium (MW > 500000, Phatmacia, 
Sweden). All mice receiving DSS 10% developed a mild superficial colitis after 
one week, only involving the colon mucosa and submucosa. After an ove11light 
fast at day 8 all mice were killed by cervical dislocation. The colon was removed, 
pericolonic fat was detached manually and faecal contents were gently extruded. 
Colon specimens were kept in formaldehyde. Glass mounted sections were 
stained (haematoxylin and eosin) for microscopic evaluation. Histological 
grading concerned neutrophil influx (0-3 points), damage (0-3) and regeneration 
(0_3)'0.23. The transverse colon was cut out and innnediately placed in standard 
Krebs' buffer (PH 7.4), containing in mmol!L: 118 NaCl, 4.7 KCl, 2.5 
CaCl,'2H,O, 1.2 MgS04'7H,O, 1.2 KH,P04, 25 NaHC03 and 8.3 glucose. 
Longitudinal transverse colon specinlens (approx. 10 mm length) were mounted 
entirely in a double jacket organ bath in carbonated (5% CO, in 0,) Krebs' buffer 
with a constant temperature of 37° C. One end of the colon specimen was 
attached to a stationary clamp. Contractile responses were measured isotonically 
under a 0.5 g load and recorded via a non-elastic wire by a PelllY & Giles 
transducer and a rectilinear ink-writing plotter. 
Carbachol (Sigma Chemicals) in increasing concentrations from 10-8 to 1Q-3 M 
was cumulatively added to the bath fluid and muscle contraction was measured. 
Equilibration of contractile response was allowed during at least I minute before 
a new dose of CARB was administered. We found a maximal muscle contraction 
at carbachol (CARB) concentration of 10-3 M. As in a pilot study precontraction 
by KCl had induced muscular inertia (data not shown) we defined maximal 
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contraction (100 %) at CARE concentration of 10-3 M and related all responses 
(contraction and relaxation) to this maximum. After equilibration at maximal 
contraction, relaxation was obtained by adding salbutamol (SALB) (generous gift 
of Glaxo Wellcome, UK) in increasing concentrations from 10-8 to 10-3 M, 
always after relaxation had reached a steady state. 
For both dlUgs log-dose-response curves were plotted (GRAPHP AD-PRISM"!). 
From these we derived the measure of contraction or relaxation as compared to a 
standard contraction induced by CARB 10-3 M (100 %). For both CARB and 
SALB the half-maximum dose (ECSOcARB, ECSOSALB) was calculated by use of 
the GRAPHP AD-PRISM"! software. Results are given in mean and 9S% 
confidence intervals. Statistical analysis was performed by a t-test for colon 
muscle response and by a Wilcoxon rank-sum test for histological scores. A 1'-
value lower than O.OS was considered statistically significant. 
Results 
Histology 
All DSS treated animals developed a mild but significant colitis. Histology 
scores fi'om DSS treated animals were significantly higher than controls. Neither 
SMS nor OCT attenuated this microscopic score (TABLE S.I). Mucosa and 
submucosa showed infiltrates of predominantly neutrophils in DSS treated 
animals. Muscle layers were not infiltrated or visibly damaged by inflammatory 
cells. 
Contraction 
Maximum contraction was derived at CARB concentrations of 10 -3 mM 
(FIGURE S.I). ECSOCARB results are listed in TABLE S.2. In controls (mean 1.1 x 
10-6 Jl1mollL) EC50CARB values were significantly lower than in the DSS-saline 
group (2.3 x 10-6 1l1l1l01lL) (I' ~ O.OOS). SMS enhanced ECSOCARB values (2.2 x 
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10-6 mmolfL) compared to controls (p = 0.03), whereas EC50cARB in the OCT 
group did not significantly differ from controls (1.4 x 10-6 llIlllOlf, P = 0.5). 
EC50cARB values in DSS treated animals were not significantly different from 
controls in both SMS (0.9 x 10-6 nunolfL) and OCT (1.1 x 10-6 nunolfL) groups 
(p = 0.5), and significantly lower than in DSS/saline (resp. p = 1.0 X 10.6 and 7.2 
x 10.6). 
TABLE 5.1 
saline 
SMS6 ftg 
OCT 0.15 ftg 
Histology score (mean ± SEM). 
control DSS 
3.0± 0.3 
3.6± 1.7 
4.2 ± 0.8 
7.2 ± 0.5* 
6.8 ± 0.6* 
8.6 ± 1.2* 
*p < 0.05 compared to control 
Relaxation 
FIGURE 5.2 depicts colon smooth muscle relaxation after maximum contraction 
at 10.3 mM CARB. Maximum relaxation was seen at SALB 10.3.5 mM. DSS 
reduced maximum relaxation significantly compared to controls (p < 0.0 I). In 
terms of percentage, SMS and OCT even showed lower relaxation compared to 
controls and DSS treated mice (p < 0.01). TABLE S.3 shows ECSOSALB results. 
SMS (S.6 x 10-6 nmlOlfL) showed significantly higher values compared to 
controls (4.7 x 10-6 mmoIlL, p = 0.02), but OCT (4.S x 10-6 llIlllolfL) did not (p = 
O.S). DSS (12.6 X 10-6 mmolfL) and DSS receiving groups that were treated by 
SMS (27.1 x 10-6 mlllol/L) or OCT (12.6 x 10-6 mmollL) showed significantly 
higher ECSOSALB values than controls with p values resp. 8 x 10.6, 8 X 10.9 and I x 
10'''. SMS even showed higher ECSOSALB than DSS (p = O.OOOS). 
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TABLE 5.2 EC50 (x 1 O.fi M) of carbachol (mean and 95 % confidence intervals) 
saline 
SMS6pg 
OCTO.IS fig 
control 
1.1 (0.4·0.8) 
2.2 (1.2-2.3)' 
1.4 (0.9-1.9) 
p < 0.05 compared to control/saline 
** p < 0.001 compared to DSS/saline 
control = control group 
saline = receiving normal saline 
DSS = dextran sulphate sodium 
DSS 
2.3 (1.7-2.9)' 
0.9 (0.7-1.2)** 
1.1 (0.8-1.3)" 
SMS 6 )1g = treated \\~th somatostatin 6 ~lglg body weight daily 
OCT 0.15 ~lg ~ treated with octreotide 0.15 ~lg/g body weight daily 
Table 5.3 EC50 (x 10'6 M) of salbutamol (mean and 95 % confidence intervals), 
For legend sec table 1. 
saline 
SMS 6 ~lg 
OCTO.IS fig 
control 
4.7 (4.1-5.2) 
5.6 (5.0-6.2)' 
4.5 (3.8-5.3) 
* p < 0.05 compared to controVsalinc 
** p < 0.000 1 compared to control/saline 
o p < 0.001 compared to DSS/saline 
Discussion 
DSS 
12.6 (9.0-16.3)" 
27.1 (19.1-35.0)'" 
12.6 (11.3-13.9)" 
Many of our concepts of colon motility control are still hypothetical. It is 
probable that circular colon muscle plays a key role in propulsion of luminal 
contents and the taeniae-like configuration of the longitudinal muscle cell 
modulates colonic reservoir function'4. The relation between altered muscle cell 
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function and disturbed motility in intestinal infla1ltlnation is largely uncertain. 111 
vitro studies show an inflammation-related decrease of maximal muscle 
contraction on muscarinic stimulation2,4,26. In earlier experinlents we found a 
marked decrease of maximum tension on CARE stimulation, which was most 
obvious in the transverse parts of the murine colon2!. In the present study, DSS· 
induced inflammation resulted in a significant higher EC50CARB, indicating a 
change of muscarinic receptor binding or cellular responsiveness during 
inflammation. This is in contrast to studies mentioned earlier, in which no effect 
f · fl' 'b'l' 242526 Thi . I' b o 1ll ammahon on receptor susceph I tty was seen" '. s mIg It 111 part e 
explained by different experimental designs, as in most cases only circular colon 
smooth muscles have been studied, whereas in our organ bath model longitudinal 
muscle changes were studied. Moreover, as we have described a marked 
regionality of DSS-induced smooth muscle impairment21, results of motility 
studies may depend on the location of colon muscular tissue taken. SMS in saline 
receiving mice also showed a higher EC50CARB whereas OCT did not change 
this value. 
However, in DSS-treated animals both SMS and OCT antagonised the DSS-
induced shift-to-the-right of the dose-response curve of CARB. In guinea pig 
colon Corleto et at. found that SMS inhibits CARB-induced contraction in the 
distal colon 13. They considered only the smooth muscle cett length on exposure 
to agonists or antagonists. That may not be as reproducible as alteration of EC50 
values. In the same study the authors state that the contractile inhibition by SMS 
depends on muscle cell resting length 13. DSS-induced diminished susceptibility 
of the muscarinic receptors in the transverse colon smooth muscle may reflect 
proximal colon stasis as is described in active human ulcerative colitis26 • Normal 
human subjects show a marked decrease of colon transit time after OCT 
exposure!!·12. Although co-localisation of membrane SMS and muscarinic 
receptors has been described", findings in our study do not support participation 
of muscarinic receptors in the OCT-derived changes of colon transit tinle. 
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Response to CARB and SALB modulated by SMS 
Normal mice receiving SMS, but not OCT, had a higher EC50CARB, reflecting 
higher thresholds for this muscle contractile agonist. SMS acts through specific 
membrane bound receptors and is likely not a muscarinic receptor antagonist, but 
interference at the level of G-proteins or second messenger systems may be 
anticipated28 ,29. 
In our model we studied isotonic contraction of the colon musculature. We found 
a significant higher EC50SALB on DSS exposure. This suggests a decrease of 
susceptibility to SALB induced by intestinal inflammation, at receptor of post-
receptor level. SMS even further increased the half-maximum concentration for 
SALB-induced relaxation. So SMS impairs SALB induced relaxation as it does 
in bronchial muscle!4. This effect is probably mediated by inhibition of the 
SALB-induced intracellular production of cAMp!4,JO, Relaxation curves 
(FIGURE 5.2) showed lower maximum relaxation after DSS exposure, As 
relaxation was based on maximum contraction, this difference of maximum 
relaxation may be due to different smooth muscle length at point of maximum 
contraction2!. Otherwise, DSS-related impaired relaxation may reflect 
inflammation-induced diminished colon wall compliance. SMS and OCT did not 
improve this changed relaxation, Reduced relaxation can result in loss of colon 
reservoir function, thus contributing to accelerated colon transit. 
In sunnllary we have found a decreased muscarinic receptor response in DSS-
induced colitis in mice transverse colon. This could be the experimental 
equivalent of clinically observed increased passage time of the proximal colon in 
IBD. The decreased response sensitivity to the muscarinic agonist CARS was 
normalised by treatment with SMS or its analogue OCT. Colon smooth muscle 
cell susceptibility to p-adrenergic stimulation by SALB was diminished in this 
experimental model. SMS and OCT further decreased the SALB susceptibility. 
Maximum relaxation length was reduced after DSS exposure, even more if DSS 
receiving animals were treated with SMS or OCT. 
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Abstract 
Somatostatin (SMS) is a small neuropeptide which acts on multiple non-neural 
targets, including the immune system and the gastrointestinal tract. In 
inflammatory bowel disease (IBD) mucosal SMS is diminished and its receptor 
density is increased. In a combined study of endoscopy, pathology, 
immunohistochemistry and octreotide scintigraphy we describe the SST 
expression in 14 patients with clinically active lED (II Crohn's disease (CD), 3 
ulcerative colitis (UC), localised in colon and/or terminal ileum. Patients 
underwent colonoscopy and [II I In-DTPA-D-Phel j-octreotide scintigraphy on 
the same day. Abdominal images were obtained after 4 and 24 hours and were 
compared with 8 non-IBD control patients. Mucosal biopsy samples and in three 
cases also bowel resection specimens were used for immunohistochemistry, that 
was performed using a polyclonalrabbit anti-solllatostatin receptor 2A antiserum 
(R2-88). Mild to moderate active of chronic inflanllllation was seen in colon 
and/or ileum specimens. Scintigraphy revealed intestinal wall [lllln_DTPA_D_ 
Phelj-octreotide uptake in lED. No correlation was found between clinical 
disease activity, endoscopy and histology on the one hand, and scintigraphy on 
the other. Immunohistochemistry showed SST2 positive staining of (sub )mucosal 
endothelium in both CD and UC, with a slight preference for active inflamed 
mucosal parts. In several CD cases superficial epithelium was positive, with a 
striking paranuclear staining. In UC patients SST2 positive fibroblasts and 
macrophages were seen. 
We conclude that SSTI positive cells are found in intestinal biopsies in active 
IBD. These receptor expression can be visualised by immunohistochemical 
techniques. Although intestinal wall [IIIIn-DTPA-D-Phelj-octreotide uptake 
was found, specificity of these images is under discussion as is its relation with 
clinical and endoscopical disease activity. 
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Introduction 
Somatostatin (somatotropin release inhibiting factor, SMS) is a small 
neuropeptide, which has two principal bioactive configurations consisting of 14 
or 28 amino acids, SMS-14 and SMS-28, SMS acts on specific G-protein 
coupled tmnsmembrane receptors in multiple targets in central nervous tissue, 
endocrine glands and exocrine pancreas, the immune system and the 
gastrointestinal tmct!, Somatostatin receptors (SST) were demonstrated by ill 
vitro radioreceptoranalysis and by ill vivo somatostatin scintigraphy with [lllln_ 
DTPA-D-PheI j-octreotide"J, [lllIn-DTPA-D-Phe Ij-octreotide binds with high 
affInity to SST2 and SSTS, and has a very low biliary excretion, making 
abdominal imaging possible, Octreotide scintigraphy has been tested elaborately 
in the past years for diagnosis of haematologic malignancies, granulomatous and 
auto-immune diseases', Receptor density correlates with disease activity and 
octreotide scintigraphy is proposed as a method for evaluation of these 
disorderss-s. 
Most ill vitro analysis of SST was performed by autoradiographic assays, SST 
expression has been found in gut-associated lymphoid tissue, leucocytes, and at 
several intestinal mucosal and submucosal cells of the gut"lO, Increased density 
of vascular SST is observed in veins sUlTounding mucosal lesions in Crolm's 
disease (CD) and ulcerative colitis (UC), and in peri-inflammatory veins in 
rheumatoid mihritis, suggesting a role in regulation of inflammatory 
processes!!'!', SMS has dampening effects on the immune system, which have 
b d 'b d' , I b 'I' 10 1l,!5 een escn e 111 vanous a oratory alUma expenments' . 
All subtypes of SST were found in intestinal tissue!6, but in the colon mucosa 
and submucosa SST2 mRNA predominates", We surveyed the presence ofSST2 
in the intestinal wall, as visualised by immuno-histochemistry with an anti· 
SST2A antibody and compared these findings with [IIIIn-DTPA-D-Phelj-
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octreotide scintigraphy in patients with active inflammatory bowel disease (lBD). 
Positivity on octreotide scintigraphy cOlwlates well with presence of the SSTi8. 
Methods 
Consecutive patients with clinically active inflammatory bowel disease (IBD), 
with ulcerative colitis (UC) or Crohn's disease (CD) of colon and/or terminal 
ileum, who were planned to have a colonoscopy to monitor disease activity, were 
enroled in the study after obtaining informed consent. Clinical disease activity 
was assessed using a Powell-Tuck scoring system (PTS) or a modified Crolm's 
Disease Activity Index (mCDAI)I9.20. Each patient was his own control 
considering active inflamed and non-inflamed mucosal parts. Controls were 8 
consecutive patients who underwent screening [III In-DTPA-D-PheIJ-octreotide 
scintigraphy. All scintigraphic imaging in controls were prepared through a 
standard laxative protocol (2 days of psyllium fibres 6 g BID, Prunacolon® 1 ml 
/ kg on the day of radio nuclide injection). 
All patients were prepared for endoscopy with oral laxative solution (Klean-
prep®). Colonoscopy took place 18 hrs later. The day before colonoscopy, 200 to 
250 mBq of rlllIn-DTPA-D-PheIJ-octreotide (10 fIg) was administered 
intravenously to 12 patients (2 UC)2.2I. Planar abdominal images were obtained 4 
and 24 hours after injection of the radiopharmaceutical. Single photon emission 
computed tomography (SPECT) was performed after 24 ms. Scintigraphic 
images were reviewed in a blinded way. 
Endoscopic evaluation of CD and UC was performed according to operative 
criteria"·24. A digital audio-visual endoscopy report was obtained fi'OIl! each 
colonoscopy and reviewed without knowledge of scintigraphic findings. Biopsies 
were taken fi'om inflamed and non-inflamed mucosa for microscopic evaluation. 
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At least five biopsies were taken each fi'om right, middle and left sided colon, 
rectosigmoid, and if possible fi'om terminal ileum. After section of biopsy and 
staining with hematoxylin and eosin, inflammation was classified 0 (absent), 1 
(mild chronic), 2 (moderate chronic and/or mild active), 3 (severe chronic, 
moderate active), or 4 (ulcerative). 
For immunohistochemistry, biopsies were obtained from the most inflamed parts 
of colon or ileum of 9 patients with CD and 3 patients with UC. Moreover bowel 
resection specimens were obtained from 3 of these patients (2 CD, I UC). 
Innnunohistochemical analysis was performed using a polyclonal rabbit anti-
somatostatin receptor 2A antiserum (R2-88) (dilution I: 1000). Specificity of the 
antiserum was confirmed by Western Blot analysis of membrane preparations of 
human neuroendocrine hunors. Biopsy or bowel resection specimens were fixed 
in formalin 10%, dried and embedded in paraffin wax. Sections (5 ,.lIn) were 
mounted on uncoated glass slides. Thereafter they were rinsed in PBS and 
reincubated for IS min. at room temperature with 10% normal goat serum in 
PBS/5% BSA. Incubation with R2-88 (dilution I: 1000) was carried out overnight 
at 4°C. The sections were rinsed twice in PBS and ineubated for 30 min at room 
temperature with alkaline phosphatase-conjugated goat-anti-rabbit 
immunoglobulin (GaRig-AP; DAKO D0487; DAKOPA TIS, Glostrup, 
Denmark) diluted I :50 in PBS/5% BSA containing 2% normal human senun. 
After the incubation the sections were again rinsed twice in PBS. Alkaline 
phosphatase activity was revealed by new fuehsine as the clu'omogen in the 
presence of levamisole to block the endogenous alkaline phosphatase activity. 
This was followed by a haematoxylin staining. Controls for 
innnunohistochemistry included omission of the primary antibody, and 
incubation with normal rabbit serum. 
Results of endoscopy, microscopy and scintigraphy were descriptively analysed. 
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Results 
Eleven patients with CD (9 female, 2 male) and 3 with UC (all male) were 
recruited. Patient characteristics are given in TABLES 6.1, 6.2 and 6.3. One 
patient had been treated with radiotherapy for prostate carcinoma (n~ 9) and had 
developed a radiation proctitis. Six had undergone surgery for Crohn's disease, at 
least two years before. Six patients used 5-ASA oral monotherapy, one did not 
receive drug treatment at the time ofthis study. One patient used 5-ASA as well 
as corticosteroids and azathioprine, one used only cOliicosteroids and two were 
on corticosteroids and azothioprine. The patients fi'om whom we obtained bowel 
resection specimens, had been treated with prednisonefSASP, and azathioprine or 
prednisonefcyclosporin in the month before surgery. 
Results of endoscopy, histology and scintigraphy are given in TABLE 6.4. 
Laxation had been sufficient in 12 IBD patients. Two UC patients still had some 
coecal faecal stasis. Histology could be obtained fi'om most colon segments and 
terminal ileum. In three patients the terminal ileum could not be reached. In one 
of these a small bowel barium follow tln'ough radiograph had been made, at 
which no abnormalities had been seen. In the two other patients ulceration of the 
ileo-ascendo anastomosis were observed. Histology showed only granulomata in 
ileum biopsies in 1 patient (n~ 3). Patchy inflammation was seen in all CD 
patients. Inflammation was also found in biopsies of intestinal segments which 
had a normal appearance at endoscopy. In UC a marked cln'onic ulcerative 
inflammation was seen in the most inflamed pat1s. 
88 
SMS receplors in lBD 
TABLE 6.1 Clinical characteristics related to Crohn's disease (CD). 
patient age flm CD history meDAl therapy 
70 f 1994 perianal disease 10 5ASA 
2 48 f 1979 R.sided colitis 12 none 
1985 hemicolectomy R. 
3 34 f 1977 ileo-cecal resection 5 5ASA 
4 46 m 1981 perianal disease 10 CS 
1989 sigmoidrese<:tion amth 
5 45 f 1994 ileitis I L.sided colitis 12 5ASA 
cs 
amth 
6 46 f 1977 i1eo-ce<:ai resection 8 CS' 
1994 stenosis i1eo-ase.slomy 
1995 resection ileo-ase.stomy 
7 39 f 1972 i1eo-cecal resection 5 azath. 
1980 re-resection CS' 
1984 ileum stenopiasly 
1986 partial ileum resectionfperianal abscesses 
1993 colostomy 
1995 stenosis neo·tenninal ileum 
8 42 f 1979 partial ileumresection 7 5ASA 
1987 re-resection 
9 60 on 1994 ileo-cecal resection 9 5ASA 
10 43 f 1982 terminal ileitis 2 5ASA 
11 35 f 1976 left-sided colitis 10 SASP 
* budesonide ileal release orally 
5ASA = 5-aminosalicylic acid 
SASP = salicylazosulfapyridine 
CS = corticosteroids 
azath = azathioprine 
R=right L=left 
mCDAI = modified Crohn's disease activity index 
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TABLE 6.2 Clinical characteristics related to ulcerative colitis (UC). 
patient age UC history PT score therapy 
12 32 1994 left-sided colitis II SASA (7 yrs) + CS (I yr) 
13 70 1967 left-sided colitis 12 CS (10 yrs) 
1987 pancolitis 
14 59 1991 pancolitis 9 SASP 
PT score = Powell-Tuck disease activity score (maximum score: 22 points) 
TABLE 6.3 
patient 
7 
II 
14 
Clinical characteristics of patients no. 7, 11 and 14 before smgcry. 
diagnosis 
CD 
CD 
UC 
therap>' before surgel)' 
SASA + CS (6 mol + esA (7 days) 
SASP + CS (4 wks) 
surgical procedure 
partial ileum resection, stricture 
plast)' 
subtotal colectomy 
subtotal colectomy 
Octreotide scintigraphy in controls showed positivity in the colon regions in all 
patients (n=8) and small bowel positivity in 4. Apart fi'om uptake in liver, spleen 
and kidneys, no additional abdominal uptake was observed. In CD intestinal 
uptake of the radiopharmaceutical was seen at 4 hI'S after injection of [III In-
DTPA-D-PheIJ-octreotide in all patients. More than 24 lu's after injection, 
radioactivity was localised in the same region (FIGURE 6.1). SPECT did not 
give additional information. In UC one patient did not show bowel uptake. One 
other patient showed small as well as large bowel positivity, which had not 
changed after 24 In·s. In 6 patients with CD increased uptake of radioactivity was 
found at sites of endoscopic disease. In 5 of these patients increased uptake was 
also noticed at endoscopically normal sites. In 3 patients endoscopic disease was 
not accompanied by increased uptake. One patient showed no endoscopic 
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changes (patient n~ I), but scintigraphy showed uptake in the right-sided colon 
and small bowel. This patient had only periods of intractable diarrhoea and was 
known with 'silent' perianal disease. Histology and scintigraphy did not correlate 
well. In 4 patients, segments which were found positive at scintigraphy, biopsies 
showed no abnormalities (patients n~ 2,4,7,9). In 6 patients inflamed intestinal 
sections did not show up at scintigraphy (patients n~ I, 3, 4, 6, 7, 8). No 
conelation comes clear between either endoscopy or histology and scintigraphy. 
SST2 innllunohistochemistry showed posivity in all but one specimens as is 
listed in TABLES 6.5 and 6.6. Patient no.9 showed no SST2 positive cells, but 
only small biopsies had bcen obtained, without remarkable inflammation. SST2 
positivity was specific as control staining with conjugate or anti-rabbit goat 
serum was negative or showed aspecific staining of non-determined cells 
(FIGURE 6.2). Mucosal or submucosal capillary endothelium was positive in 10 
out of II SST2 positive patients, most pronounced in the proximity of leukocyte 
infiltrates. Superficial epithelium showed SST2 positivity in 6 CD patients. A 
remarkable paranuclear staining was seen in these cases. Crypt epithelium 
positivity was observed in 2 CD and all 3 UC patients. Focal positive plasma 
cells, ganglion cells and macrophages were seen in CD patients. UC patients 
showed in all cases positive macrophages. 
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TABLE 6.4 Results of endoscopy, histology and scintigraphy. 
Patient Endosco~l: Histolog\'* Scintigra~hy 
Ileum NI po> 
R.(oIOIl N po> 
M.colon N .. , 
L. (olon N .. , 
rectosIgmoId N 
"" ileum N 
"" U<C~'«DdoS!omy ulHn po> 
R. colon N po> 
.\1, colon N , .. , 
L. <OIOD N 0 po> 
uC[Oligmold N po> 
ilenm N 
"" Ueusc(udo!!om) Pltus po> 
R. (oron N po> 
~I. <olon N 
"" 
L. (olon N po> 
rutoslgmold N , 
"" Ileum N 0 po> 
R. (olon N 
"" 
.\1.(o[on N 
"" L. (olon 'J}tb.ma 
"" 
udodgmold "!cnath-e lIenests 
"" Ueum aphtbn 
"" R. colon N po> 
M. (olon N po> 
L.(oloo aphthae po> 
rutoslgmold N po> 
il,um NI 
"" UN~lcendOltom)' "Icnathe lleuO!!! po> 
R. (olon N po> 
,\1. (olon N po> 
L. (olon .pbtb .. po> 
Hclo,[gmoid apb/hH p .. 
Ileum ulnrotheslf"o,!s 
"" R. (olon N po> 
~1. (olon N p .. 
1... <olon N p .. 
uuollgruold N 
Ileum NI 
"" Ileo~l<elldoltom)" ulcus , p .. 
R.colon N 0 p .. 
;\1.(01011 N 0 .. , 
L. <OIOD N 0 
"" reUoslgmold N 0 .. , 
il,um N 0 po> 
Ilroascendoi!om} 'phthn 0 p .. 
R. (olon N 0 p .. 
,\I, «)lon N 
"" L. (01011 N .. , 
u<losigmold radbtlOIl pto<tltls .. , 
" 
UeubI Nl 
"" R. <olon p,tudopol)ps po> 
~I. (olou N 
"" L. colon N 
"" 
r«lo,lgrnoid N 
"" 
" 
lleubl N 
"" R. <olon 1f}lhebla 
"" 
• sIt ~IHhod, 
~l. (olon er}lberna "., 
L. <olon atroph)' 
"" 
NI = not hup«led 
rt<!o,lgblold 'poradic ulcer, 
"" 
N ~ nocblal 
" 
1J.:ubI NI p .. 
R. <olon supufJdll ulcus po> po, = pOlit;,t 
~1. <olon ulcers po. ntg '" mgatht 
L. <olon ulceu 
"" U<IOllgblotd aI, ... 
"" 
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TABLE 6.5 Results of SST2 imnnmohistochcmistry I (biopsy and bowel resection 
specimens), 
Patient colo nfin testines stain positive negative 
7 
7 
II 
II 
14 
14 
anastomosis iIco- SST2 superficial epithelium (paranuclear), esp. near infiltrate 
asc. (endothelium not available) 
corlj, none 
ileum resection SST2 superficial epithelium (paranuclear) submucosal 
endothelium (near infiltrate or ulcers) endothelium 
leukoc)1e-
infiltrate 
rabbit endothelium (focal) (neg. were SST2 is pos.) epithelium 
conj. none 
colon biopsy SST2 crypt epithelium (cellmcmbrane) 
macrophages (focal) 
capillary endothelium (++) 
rabbit aspee. 
conj. non-detemlined cells (paranuclear) 
colon resection SST2 crypt epithelium ruacrophages 
endothelium (mucosa) 
endothelium (muse. ext.) and surrounding infiltrate 
conj. none 
colon biopsy SST2 endothelium 
conj. none 
colon resection SST2 endothelium (++) (submucosal: focal) 
t1broblasts Imacrophages (near muse. mucosae) 
crypt epithelium (focal) 
conj. none 
Discussion 
Somatostatin is a small neuropeptide, which acts in various tissues and has 
mainly inhibitory effectsl. Its specific receptors are found in the the central 
nervous system, the immune system and the digestive tract. Five distinct SST 
have been identified (SSTI-5), each with different binding characteristics for 
somatostatin and different SMS analogues including octreotide25,26, In vivo SST 
expression can be revealed by scintigraphy with indium-labelled octreotide. This 
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[I I IIn-DTPA-D-Phelj-octreotide (pentreotide) is mainly bound to subtype 2 and 
5". The application of[lll In-DTPA-D-Phelj-octreotide scintigraphy has been 
well established in the diagnosis and staging of neuroendocrine tumours". 
Receptor positivity is also found in breast cancel', lung tumours, malignant 
lymphoma and granulomatous disease27.". Nonnally, uptake of [I I IIn-DTPA-D-
Phe Ij-octreotide is seen in the pituitary, thyroid, liver, spleen and both kidneys2s. 
It has a largely renal clearance and only small amounts show up in the faeces21 . 
[I I lIn-DTPA-D-Phelj-octreotide scintigraphy is used for staging and 
monitoring abdominal lesions, like gastrin om as and other neuroendocrine 
tumours, because these diseases show high receptor density29. However, a small 
amount of intestinal background acitivity due to faecal elimination of [Ill In-
DTPA-D-Phe Ij-octreotide is seen in most cases 18.30.33. 
We are not aware of other studies conceming intestinal SST scintigraphy ill vivo 
in IBD. In controls mainly large bowel activity was seen. This could be due to 
ineffective bowel cleaning, bowel imaging being related to faecal radioactivity 
content. In all CD patients and in one UC patient intestinal somatostatin 
scintigraphy with [llIIn-DTPA-D-Phelj-octreotide was found positive. As 
scintigraphy and colonoscopy were performed on the same day, the effectiveness 
of the laxative protocol could be visually checked. In our study laxation had 
been sufficient in all but two patients who underwent colonoscopy. No 
unequivocal relation of receptor imaging and either clinical 01' endoscopic 
disease activity was observed. Normal endoscopic findings often went together 
with increased uptake of radioactivity. In patients with clinical lBD symptoms 
scintigraphy was found abnormal. Intestinal [lllIn-DTPA-D-Phel]-octreotide 
uptake did not show an unequivocal relation with inflammatory changes at 
histologic evaluation of mucosal biopsies. Octreotide scintigraphy therefore is 
unsuitable for monitoring the localisation of involved intestinal segments in lBD 
as well as disease activity. The specificity of increased intestinal uptake of 
[Ill In-DTPA-D-Phel]-octreotide in active lBD is disputable. Granulomatous 
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diseases as well as diseases with activated mononuclear leukocytes show SST 
expression. Receptor density is correlated with disease activity5.6. 
A new polyclonal anti-somatostatin receptor antibody was used in our study. 
This antibody is specifically bound to the SST type 2A. We were able to show 
that this method can be applied to formalin fixated and paraffin waxed tissue 
sections. In the biopsy specimens the mucosal and often also the submucosal 
endothelium was SSTI positive. Most lBD specimens also showed SST2 
positivity at superficial epithelium and crypt epithelium. At many spots this 
receptor positivity was seen neal' leukocyte infiltrates. SST2 could not be 
reveiled at leukocytes, despite reported positivity in vitro, most likely conceming 
a different SSTl'. In patients consuming cOlticosteroids SST2 was seen in 
qualitively comparable amounts as in those on 5ASA monotherapy. This 
indicates that corticosteroids do not pel' se dowmegulate SST expression. 
Epithelium positivity was not only seen at the cell membranes, but also 
paranuclear. This could be a non-specific finding, as some of the anti-rabbit goat 
antibodies also showed paranuclear staining in non-determined cells. However, 
earlier studies also describe an increased density of SST in intestinal epithelium 
at autoradiographl5.l6. The effects of SMS on intestinal epithelium is associated 
with inhibition of regeneration, but might also have an effect on mucosal 
permeability or secretion37,3S, 
SST are also located in the intestinal lymphoid tissue, like palatine tonsils, 
germinal centres of intestinal lymph nodes and Peyer's patchesl9. This receptor 
expression is seen in normal intestinal tissue, without inflammatory changes, and 
concerns most likely SST type I receptorsJ6. 
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TABLE 6.6 Results of SST2 immunohistochemistry 2 (biopsy specimens), 
patient biopsy stain posHh'c negative 
colon SST2 endothelium (++) 
endothelium submucosa 
plasma cells (paranucl.) (focal) 
superficial epithelium (paranllcl.) 
crypt epithelium (focal) 
submucosal Iymphe vessel 
conj. none 
2 ileo-asc. anast. SSTl superficial epithelium (paranucl.) 
conj. none 
3 colon SST2 endothelium infiltrate 
plasma cells (paranue!.) (focal) 
superficial epithelium (paranuc1.) 
conj. none 
4 colon SSTl endothelium epithelium 
rabbit non-detennined cells (paranucl.) 
conj. none 
8 i1ea-asc. auast. SST2 endothelium 
superficial epithelium (paranllcl.) 
ganglion cells (focal) 
fibroblast-like cells (focal) 
conj. none 
9 i1ea-asc. anasl. SST2 none 
conj. none 
10 colon SST2 endotheliwn 
superficial epithelium (paranllcl.) 
conj. none 
12 colon SST2 endothelium 
submucosal endothelium 
crypt epithelium 
fibroblasts / macrophagcs 
conj. none 
13 colon SST2 endothelium (focal) 
crypt epithelium (focal) 
fibroblast~like cells (focal) 
corlj. none 
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In lBO, increased expression of these receptors is obvious in walls of 
intramucosal veins, but not in arterial walls 12• The role of this increased receptor 
content still has to be disclosed. Speculations on interference with or 
counterregulation of pro· inflammatory, vasodilatative effects of other 
neuropeptides (vasoactive intestinal peptide, substance P) have been made'. 
Regulation of local blood flow in intestinal inflammation is anticipated. In our 
biopsy series endothelial SST positivity could be a comparable phenomenon. 
Although selection bias might playa role, the SST positive endothelium we saw 
in the bowel resection specimens was particularly located near active inflamed 
sites. A role in local inflammatory control is suggested, as described in intestinal 
granulomata in Schistosoma manson; induced inflammation 40. Inhibition of 
endothelial permeability by octreotide has been described". Increased SST 
density could also result fi'om a negative feedback effect fi'om the diminished 
mucosal SMS content42-44 . However, the same phenomenon is observed in 
studies of colon carcinoma. A marked density of SST has been described in 
surrounding vessels of human colon adenocarcinoma, without signs of 
inflammation 45. In colon adenocarcinoma this increased receptor density can not 
be visualised by in vivo scintigraphy, because of interference with radioactivity 
in intestinal faecal content. 
An interesting observation is the receptor positive fibroblast cells in UC bowel 
wall. SST2 have been described in lung and intestinal fibroblasts46 • This might 
reflect the inhibitory function of effect of SMS on fibroblasts and histiocytes4', 
but in other studies such an effect is not observed4'. This variation of 
observations could be a result of the presence of different SST subtypes. 
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FIGURE 6.1 Octreotide scintigraphy 24 hours after iqjectiol1 in patient with erolm's disease. 
Left panel: anterior view. Right panel: posterior view. 
FIGURE 6.2 Colon biopsy specimen ofChrohn's disease patient with example ofpositivc 
SST2A staining in crypt epithelium 
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In conclusion, we have demonstrated that a polyclonal anti-SST antibody can be 
used to demonstrate the SST type 2A positive cells, i.e. mucosal and submucosal 
endothelium at inflamed bowel wall biopsies, as well at supertical and crypt 
epithelium in active lBD. In UC a striking receptor positivity is seen at mucosal 
fibroblasts and macrophages. The presence of SST at these cells probably opens 
up new perspectives for IBD therapy with SMS or SMS analogues, which could 
have inhibitory effects on target cells. Intestinal uptake of [I I IIn-DTPA-D-
Phel]-octreotide in IBD was observed, particularly in CD, possibly indicating 
increased SST type 2 density. As no relation with clinical, endoscopical or 
histological disease was observed, octreotide scintigraphy is not suitable for 
monitoring disease activity or localisation. 
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OCTREOTIDE IN PATIENTS WITH ACTIVE ULCERATIVE 
COLITIS TREATED WITH HIGH-DOSE CORTICOSTEROIDS 
(OPUS 1) 
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Abstract 
In ulcerative colitis the intestinal somatostatin (SOM) content is reduced. The 
neuropeptide SOM has several immune-inhibitory effects. In vitro SOM 
diminishes activity of intestinal lymphocytes and peripheral blood monocytes. Its 
long-acting analogue octreotide has beneficial effects on mucosal damage in 
acute experimental acetic acid colitis in rats. 
The aim of the study was to determine the potential benefits of octreotide as 
treatment of patients with severe ulcerative colitis treated with high-dose 
cOliicosteroids. 
We studied 42 patients with severe ulcerative colitis (more than to points on 
Powell-Tuck scoring system and mucosal disease Reatly grade III or IV). In a 
multi-center, double blind, placebo-controlled trial all patients were treated with 
oral 5-ASA (1.6-2.4 g daily) and high-dose cortico-steroids (tapering off fi'om 
60-80 mg daily). They were randomly assigned to receive subcutaneous placebo 
(n=22) or octreotide 500 Ilg (n=20) thrice daily during 21 days. Clinical and 
endoscopic disease activity, histology and laboratory parameters were obtained 
during the study period. 
Clinical disease activity for both octreotide and placebo were not significantly 
different at baseline and after 21 days of treatment. Endoscopic disease activities 
(mean ± SD) changed both signficantly ii'om 12.5 ± 4.7 to 7.2 ± 5.3 for 
octreotide and ii'om 11.5 ± 5.0 to 5.0 ± 3.4 for placebo (octreotide vs placebo: 
NS). Seven patients ii'om both groups received additional treatment (colectomy 
(n=6), cyclosporin (n=I)). Adverse events occurred equally in both groups. 
Subcutaneous administration of octreotide 500 Jlg tln'ice daily is not of additional 
benefit as adjuvant therapy to high-dose corticosteroids in severe ulcerative 
colitis. 
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Introduction 
Standard medical treatment of ulcerative colitis (UC) is based on 5-
aminosalicylates (5-ASA) and corticosteroids. Many patients however fail to 
respond adequately to standard therapy and this has stimulated the search for 
other strategies!. Most new approaches are still experimental, but 
immunosuppressive dl'l1gs as cyclosporin and azathioprine are increasingly being 
used in clinical practice for patients who do not improve on standard therapy. 
Although innnunosuppressives are effective in colitis, up to 35% of patients with 
severe UC will require a colectomy within one year2. Most new drugs for 
inflammatory bowel disease (IBO) are aimed at suppressing cytokine or 
eicosanoid production or effects, or at scavenging free radicals. 
Recently, attention has been drawn to the possible role of neuropeptides such as 
substance P, vasoactive intestinal peptide, calcitonin gene related peptide and 
somatostatin in inflammation of the gut. Somatostatin (SMS) is particularly 
interesting, as it has several inhibitory effects of the immune system3• SMS levels 
in mucosa and submucosa of IBO patients were repo!ied to be reduced'·s. The 
long acting SMS analogue octreotide attenuated colonic mucosal damage in an 
experimental animal model'. These experiments suppOli the possible protective 
role of SMS or octreotide in mucosal inflammation in IBO. 
Octreotide, in combination with standard therapy, should influence a broader 
range of inflammatory mediators and hence could be beneficial in patients with 
IBO. We therefore performed a multicentre, double-blind, randomised, placebo-
controlled trial of octreotide added to standard treatment regimens of 5-ASA and 
co!iicosteroids in patients with severe UC, to determine whether octreotide could 
attenuate symptoms and avert colectomy or cyclosporine. 
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Patients and methods 
Patient selection 
Patients with UC fulfilling the in- and exclusion criteria were recruited for 
participation fi'om in- and outpatient populations of pmiicipating hospitals. 
Hospitals qualified if they had at least 8 patients with severe UC pel' year, the 
possibility of videotaped colonoscopy and proven experience with GCP clinical 
studies. All hospital Ethical Committees approved the protocol. Patients were 
selected for study if they were aged 18 to 65 years, suffering fi'om clinical active 
UC with 2: 10 points on Powell-Tuck scoring system' and mucosal disease 
activity grade III 01' IV (Heatly) at baseline8• Not more than 2 days elapsed 
between endoscopy at baseline and the stmi of therapy. Patients with other causes 
of colitis, especially proven Crolm's disease (biopsy diagnostic for Crohn's 
disease, and/or small bowel involvement, and/or intestinal fistulae, and/or skip 
lesions on colonoscopy), and patients with a history of alcohol 01' drug abuse, 01' 
with concomitant microbial infection (Salmonella, Shigella, Yersinia, 
Campylobacter jejuni, presence of parasite eggs 01' cysts), heati, lung, kidney 01' 
liver disease were excluded fi'om the study. Patients who used other medication 
for treatment of IBD were excluded, except for 5-ASA and corticosteroids, 01' at 
least 3 months of constant dose of azathioprine. Pregoancy was excluded and 
patients were encouraged to take contraceptive measures. 
Treatment protocol 
After obtaining informed consent patients were randomly assigned to one of two 
treatment groups. In a double blind fashion either octreotide (500 ~g) 01' placebo 
was administered subcutaneously three times daily. After baseline assessments 
the trial drugs were given during a maximum period of 21 days. Concomitant 
treatment consisted of an oral daily dose of 1.6 to 2.4 g 5-ASA and prednisone 01' 
prednisolone once daily intravenously 01' orally, staliing with 60 - 80 mg in the 
first week of treatment, tapering off by 10 to 20 mg per week. If needed, at any 
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point surgery would be performed or therapy with immunosuppressive drugs 
(e.g. cyclosporin) would be added. Patients were allowed to take all medication 
outside the centre, provided that they were able to self-administer the 
subcutaneous injections and that sufficient medical control on this procedure 
could be wananted. 
Clinical disease activity 
Clinical disease activity was evaluated at baseline and during therapy (study day 
1 to 10 and 21). Grading was done according to the Powell-Tuck scoring system, 
including the rating off well being, abdominal pain, bowel frequency, stool 
consistency, bleeding, anorexia, nausea or vomiting, abdominal tenderness, eye, 
mouth, joints or skin complications, body temperature and biochemical 
parameters7• Safety assessments included recording of all adverse events, clinical 
laboratory tests and vital sigus. 
Endoscopy 
Disease activity was assessed at baseline and during therapy (study day 10 and 
21) by video or photo-recorded colonoscopy or sigmoidoscopy. In a standardised 
procedure the endoscope was introduced as far as the level of transition between 
normal and abnormal mucosa. Endoscopic disease activity was analysed by a 
blinded end-point committee, comprised of three experienced endoscopists, that 
reviewed all videotapes. Endoscopic grading of the most inflamed patt involved 
erythema, vascular pattern, fHability, granularity, spontaneous bleeding, 
occunence and severity of ulcers, extent of ulcerated surface and presence of 
mucopurulent exudate. All parameters were scored from 0 to 2 points. Four 
grades of activity were recognised according to the sum of all parameters: 
inactive disease (0-3), mild disease (4-7), moderate disease (8-12) and severe 
disease (13-18). 
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LaboralGlJ' 
Histologic disease activity by biopsy for confirmation of UC was assessed at 
baseline and during therapy (study day 21). Biochemical and haematological 
parameters indicating disease activity were measured at baseline and during 
therapy (study day I, 3, 7, 10 and 21). These parameters consisted of 
haelllogiobin, leukocyte count (including differential counts), orosomucoid or C-
reactive protein, and albumin. 
Final allalysis 
All clinical evaluable patients were included in the standard efficacy analysis. 
Primary parameters of efficacy were time to reduction (more than 3 points for at 
least 3 consecutive treatment days) in clinical disease activity during the first 10 
days of therapy, and endoscopic and clinical disease activity as assessed on day 
10 and 21. Secondary parameters of efficacy were time to surgery decision 
within the study period (op to day 21) and time to addition of therapy with 
imlllunosuppressives. Efficacy was also evaluated in an additional intention-to-
treat analysis, including all patients in whom the study was initiated. Data were 
descriptively analysed. ANOYA or Kruskal-Wallis analysis of variance were 
used to test for overall differences between the groups. Further testing was done 
by t-test or Mann-Whitney (U) test / robust rank-order test. 
TABLE 7.1 Patients characteristics. 
octrcotide placebo 
N 20 22 
M/F 13/7 13 I 9 
mean age ± SD (yr) 35 ± 10 42± 12 
therapy at study start 
5·ASA ISASP 20 22 
topical corticosteroids 1 1 
oral cortic{)steroids 4 9 
azathioprine 
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Results 
Patients characteristics 
Inclusion criteria were met in 42 patients. Twenty patients were randomised to 
octreotide treatment, 22 received placebo (TABLE 7.1). All patients had been 
treated with oral 5-ASA, 15 also had been taken corticosteroids and 2 had been 
on azathioprine. Tln'ee patients from the placebo group were withdrawn from 
study: I patient on her own request due to unbearable disease activity, I for 
Campylobacter enteritis, I for oliguria. Adverse events were reported in 12 and 9 
patients fi'Oln octreotide and placebo treated groups respectively (TABLE 7.2). 
Two severe adverse events (disease exacerbation and non-toxic colon dilatation) 
were seen. 
TABLE 7.2 Adverse events. 
octl"cotide (n-12) 
hyperglycaemia 
pain, redness and swelling arOlUld injection site 
tonsillitis 
abdominal bloating 
non-toxic dilatation transverse colon 
paresthesia in the tongue 
swelling of cervical lymph nodes 
flushing 
cI)1hema nodosllIll 
p),odcnna gangrenosmll 
placebo (11-9) 
urticaria 
progressive diarrhoea 
anele oedema 
blurred vision 
nausea 
headache 
oliguria 
Campyiobacter enteritis 
progressive abdominal cramps and diarrhoea 
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FIGURE 7.1 Clinical disease activity, Powell-Tuck Score, means and standard deviation per 
assessment day for total scores, 
Cli1lical disease activity 
Mean clinical disease activity (95 % confidence interval) at first assessment was 
12.9 (12.0-13.8) for octreotide and 13.6 (12.6-14.6) for placebo treated patients 
(NS). During the treatment period 7 patients received additional treatment for 
unresponsive disease to conservative management (octreotide n=3\ placebo n=4). 
No differences in time to additional treatment were seen between the 2 groups. 
Gne of these patients received cyclosporin after 2 weeks ( octreotide group), all 
others underwent surgery after 2 to 3 weeks. A similar decrease of clinical 
disease activity was seen in both groups (FIGURE 7.1). At day 10 mean clinical 
disease activity (95 % confidence interval) was 5.4 (3.1-7.7) for octreotide and 
6.4 (4.1-8.7) for placebo, at day 21 these scores were 3.5 (2.1-4.9) and 4.0 (2.3-
5.7) respectively (NS). No significant differences of individual scoring 
parameters were seen, even not for bowel ti'equency (FIGURE 7.2). 
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FIGURE 7.2 Powell·Tuck Scoring system, means and standard deviation for bowel 
frequency. 
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FIGURE 7.3 Powell-Tuck Scoring system, means and standard deviation for abdominal 
tenderness. 
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Abdominal tendemess tended to decline more rapidly in the octreotide group 
(FIGURE 7.3, NS). Significant reduction of clinical disease activity (more than 3 
points for at least 3 consecutive treatment days) was seen in 17 octreotide and 15 
placebo treated patients (NS). Time to reduction in clinical disease activity 
during the first 10 days of therapy was 5.6 (4.5-6.7) and 5.7 (4.9-6.5) days 
respectively (NS). 
Endoscopic disease activity 
From 24 patients (II octreotide) endoscopy videos were obtained at baseline, at 
day 10 and 21. Mean endoscopic scores decreased during treatment. No 
significant differences between the 2 treatment groups were seen on either point 
of evaluation (TABLE 7.3). 
TABLE 7.3 
baseline 
day 10 
day21 
Endoscopic disease activity score mean scores and 95 % confidence intervals. 
octreolide 
12.5 (10.4-14.6) 
9.2 (6.6-9.6) 
7.2 (4.9·9.5) 
placebo 
11.5 (9.4·13.6) 
7.8 (6.0·9.6) 
5.0 (3.6·6.4) 
Labora/ol)' assessments 
Increase of fasting glucose levels was seen in I octreotide and I placebo patient, 
values respectively 8.9 and 11.6 mmollL. Two patients in the octreotide gronp 
showed slight increase of ALAT/ASAT and gamma GT (> 2x upper limit of 
normal). Mean C-reactive protein decreased during treatment. No significant 
differences between the two groups were seen concerning haemoglobin, 
leukocytes, albumin, C-reactive protein or orosomucoid. 
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Discussion 
The treatment of severe UC is a challenge for clinicians. High-dose 
corticosteroids, administration of other immunosuppressive drugs, like 
cyelosporill, are often inevitable. Despite intensive immunosuppressive therapy 
up to 30% of these patients are non-responders or poor-responders and need 
colectomy, immediately or after several months2.9.IO• Therefore, developing new 
therapeutic strategies for acute severe UC is wmranted. 
Pro- as well as anti-inflammatory actions of neuropeptides have been described. 
SMS is a key immunoinhibitory neuropeptide and its clinical anti-inflammatory 
properties have been demonstrated3•1l • Proliferation and cytokine release of 
intestinal lymphocytes is inhibited by SMS and SMS analogues 12-15. An increase 
of SMS receptors has been observed in germinal centres of the gut associated 
lymphoid tissuel6 and there is elose contact of receptor bearing cells with 
developing innnunocytes l7. A decrease of mucosal SMS concentration in active 
lED has becn observed'·18.19. This only holds for the colon in UC or Crolm's 
colitis, as no differences of SMS content was seen in normal and diseased 
terminal ileum in Crohn's disease'. Disease activity and SMS content are 
inversely related'·5. Octreotide was found to be effective in inhibiting the 
intestinal inflannnation in acetic acid-induced colitis in rats giving a significant 
decrease of primary as well as secondary inflammatory mediators6. Other clinical 
and experimental studies provide evidence for an anti-inflammatory effect of 
SMS analogues, which may potentiate the effects of cOliicosteroidsll.20.21. 
Case reports on successful treatment of intestinal inflanm1atory disorders have 
been published"·2l. However, as far as we know, controlled clinical trials of 
octreotide in the treatment of IBD have not been performed. In our trial we 
administered octreotide as an adjuvant therapy to high dose corticosteroids in 
severe UC. Effects of adjuvant octreotide did not differ from placebo, as 
measured by a decrease of clinical disease activity, laboratory parameters and 
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endoscopic disease. Octreotide did not affect leukocyte count. Hyperglycaemia 
was only observed in 1 patient, who was previously known to have a 
corticosteroid-induced diabetes. When comparing all individual parameters in the 
clinical disease activity score (Powell-Tuck) a trend towards a more rapid decline 
of abdominal pain and tendel'lless was observed. However, statistical significance 
was not reached. As octreotide changes visceral pain perception and reduces 
inflanllllatory hyperalgesia, this could be an explanation for this 
phenomenon'4.". An interesting finding is that octreotide did not affect bowel 
fi'equency and stool consistency, suggesting a lack of interaction with colon 
resorptive capacity and muscular activity. 
In conclusion, we found no additional benefit of octreotide administration in 
patients with severe UC, who are treated with high-dose corticosteroids. 
Octreotide did not improve response to cOliicosteroid therapy. The already low 
incidence of smgical procedmes and administration of cyclosporin did not 
decrease. 
This research was sponsored by NOVGl'fis, Basle, Switzerland 
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GENERAL DISCUSSION AND CONCLUSIONS 
Somatostatin (somatotropin release inhibiting factor, SMS) has a large number of 
biological effects, acting mainly as an inhibitOlY neuropeptide. SMS is present in 
the central and peripheral nervous system, the digestive tract and the immune 
system. Several ill vitro and in vivo studies have shown that SMS is involved in 
inflannnation. The studies described in this thesis were aimed at determining 
whether SMS plays a role in the modulation of intestinal inflannnation and 
whether SMS analogues might be of benefit in the treatment of human idiopathic 
inflammatory bowel disease. As reviewed in chapter 2, there is good evidence 
that SMS inhibits cytokine release by several types of innnunocytes, including 
the intestinal epithelial lymphocytes. SMS or SMS analogues may modulate 
intestinal inflammation, at least in animal models 1-3. In human inflammatory 
bowel diseases (!BD), the mucosal SMS content is decreased, and this could 
possibly contribute to ongoing inflannnation. Human white blood cells, including 
intestinal lymphocytes, have SMS receptors, and it is likely that suppressive 
effetcs of SMS on leukocyte function are at least in part specific receptor-
mediated effects. Intestinal leukocyte proliferation and gannnaglobulin 
production are inhibited by SMS. As most studies concelll test tube conditions, 
the overall effects of SMS in intestinal inflannnation when administered to 
11lIman subjects is not well known. In an animal model, the SMS analogue 
octreotide attenuates acetic acid-induced colon inflannnation3. Although in that 
study the colonic level of secondary innnunologic mediators (platelet activating 
factor, leukotriene B4) was decreased, no evidence is given of direct interaction 
between SMS or octreotide and immunocytes. It is possible that a non-
immunological mechanism might be involved in the beneficial effect of 
octreotide in acute acetic acid-induced colitis. Pancreas proteolytic enzyme level 
is increased in faeces of patients with active colitis 4• Octreotide suppresses 
pancreas secretion5, resuIting in lower intraintestinal levels of proteol)1ic 
enzymes. This could make the colon mucosa less susceptible to acetic acid. 
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Cytoprotective effects of SMS, possibly related to diminished pancreas secretion, 
have been repOlted in experimental pancreatitis". Other protective effects may 
result from increased blood perfhsion, as has been described in several 
experimental pancreatitis, liver ischemic models and experimental intestinal 
ischemia studies7-9. 
Table 8.1 Dextran sulphate sodium-induced colitis: relevance of animal model compared 
to human inflamtnatory bowel disease. 
bacterial ilwolveruent 
genetic influence 
primary macrophage dysfunction 
TH lymphoc)1e pattern in subacllte phase 
patchy inflammation of colon 
small bowel lesions 
malignant degeneration in chronic phase 
DSS-colitis ulcerative colitis Crohn's disease 
+ 
+ 
+ 
TH, 
+ 
+ 
+ 
+ 
? 
TH, 
+ 
+? 
+ 
? 
TH, 
+ 
+ 
+ 
Dextran sulphate sodium (DSS}-induced colitis in rodents is a very reproducible 
model of experimental colitis. Colitis is induced by dissolving DSS 10 % 
(weight/volume) in the drinking water of laboratory animals (BALB/c mice). 
The model has several sinlilarities with ulcerative colitis (TABLE 8.1). DSS-
induced colitis is characterised by neutrophil infiltration, loss of crypt 
architecture and drop-out of mucosal goblet-cells. Granulomatous inflammation 
is not seen and inflammatory changes are mild and superfical. The entire colon is 
inflamed, but inflammatory changes can be patchy, in contrast to ulcerative 
colitis. As in human ulcerative colitis, DSS colitis is associated with low colon 
levels of interleukin-IO, probably reflecting TH,-Iymphocyte dysfunction. In a 
recent study administration of IL-I ° was found to reduce inflammation in DSS-
induced colitis, suppOlting a TH,-lymphocyte dysfunction lO • Others report an 
increase of predominantly THJ activity in cln'onic DSS colitisll • The exact 
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mechanism ofDSS-induced colou damage is still not entirely understood. It has 
been suggested that DSS interferes with colon macrophage fimction, which is 
impaired by DSS (FIGURE 8.1)12.13. 
In chapter 3 and 4 we found supportive evidence for this, reflected by low colon 
IL-6 levels. This is in contrast with the elevated intestinal mucosal and intestinal 
fluid IL-6 levels repOlted in human ulcerative colitis"·15• Macrophage 
dysfimction results in an inadequate response to bacterial invasion and 
subsequent inflammation of the colon mucosaI6,!'. Other mechanisms may be 
involved. DSS might change mucosal epithelial integrity and permeability, but 
this is rather speculative I'. Activation of non-intestinal patts of the immune 
system could be involved, inducing intestinal inflammation from peripheral 
blood. Our results do not support commitment of peripheral leukocytes as 
cytokine content of thymus and spleen did not cbange in DSS treated mice. 
Neuropeptides may be impOltant in development of DSS-induced colitis. Nerve 
damage by capsaicin intensifies colonic inflammation by DSS 19. It is not known 
whether colon SMS content is affected in DSS-induced colitis. In a different 
experimental colitis model (trinitrobenzene sulphonic acid) reflecting acute 
inflannnation and severe mucosal damage, colonic wall SMS innnunoreactivity 
was only slightly affected2o. Other neuropeptides (substance P, vasoactive 
intestinal polypeptide, calcitonin gene related peptide) promote inflammation in 
different experimental inflammatory models and are involved also in IBD21 •26. 
SMS could possibly oppose the pro-inflannnatory activity of other neuropeptides 
like substance p2'. 
In acute DSS-induced colitis the inflammation score, which is largely determined 
by mucosal neutrophil infiltration, was diminished by SMS if administered 
before DSS exposure, as described in Chapter 3. The mechanism of this 
protective effect is not known. Leukocyte migration may hampered by SMS2',29, 
although conflicting data exist]o.]I. 
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FIGURE 8.1 Proposed pathophysiological mechanism of dextran sulphate sodium-induced 
colitis: DSS hampers colon mucosal macrophage opsonisatioll, so that luminal bacteria are able 
to enter colon mucosa and induce mucosal inflanunation (shaded arrows: inhibition). 
Interference of SMS with leukocyte adhesion may be involved32•J4, probably by 
decrease of adhesion molecules35,36. Direct inhibition of intestinal lymphocytes is 
not likely as T-ceH derived interleukin levels are not affected by SMS. We found 
that SMS fhrther reduced already low colon IL-6 concentrations in DSS-induced 
colitis, probably reflecting macrophage inhibition added to the effect of DSS. 
Inhibition of macrophage activity by SMS has been repOlied before37,38. 
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In chapter 4, neither SMS nor its long-acting analogue octreotide were found to 
attenuate intestinal neutrophil infiltration in sub-acute DSS-induced colitis, when 
administered simultaneously with DSS during seven days. Animals receiving 
SMS or octreotide without DSS even showed enhanced mucosal and submucosal 
neutrophil content. Although SMS under certain circumstances promotes ill vitro 
leukocyte migration, the mechanism of this phenomenon is not well understood. 
Colon wall interferon (IFN)-y was not detectable, probably not playing an 
important role at the studied stage of DSS-induced colitis. In the subacute DSS 
model, the already low IL-lp, IL-6 and IL-IO levels were further reduced by 
SMS aud octreotide. That may imply that prolonged SMS administration impairs 
TH,-lymphocyte function. IL-IO is a key inhibitory cytokine in intestinal 
infiammationJ9 and severe colitis develops in IL-IO knockout mice4o• IL-IO 
treatment may be of benefit as well in DSS-induced colitis as in human 
lBD lOAl .". Low SMS-induced colon tissue IL-IO levels could possibly aggravate 
DSS-induced infiannnation in the post-acute phase. Future research could focus 
on the influence of SMS or SMS analogues on the release of secondary mediators 
like prostaglandins, leukotrienes and nitric oxide in the cln'onic stage of DSS-
induced colitis, and the evolution of chronic DSS colitis, which develops after 
repeated exposure to DSS altemating with normal drinking water. In that scope 
colon carcinoma development after several months of DSS-exposure is 
• . 4J 44 • I 'b' . f mterestmg , , as 111 11 lhon 0 human colon carcinoma growth by SMS 
analogues has been reported45•46• 
Frequent bowel movements are COllllllon in active lBD, and are often difficult to 
manage. Several clinical studies have shown a beneficial effect of octreotide on 
intractable diarrhoea of various causes 47. SMS may modulate bowel secretion 
and activity of enteric nerves, smooth muscle cells and ilmllune cells. Most 
research ill this field concern SMS affecting small bowel secretion and motility. 
In Crohn's disease of the small bowel SMS certainly can be of value as 
antidialThoeal agent4S . Its role in ulcerative colitis still has to be clarified. Human 
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studies showed increase of transit time in the normal colon during administration 
of SMS or octreotide. As far as we know, no studies of SMS treatment in colitis 
have been published before. The DSS model is suitable for studying 
inflammation-induced muscle dysfunction, without (visible) muscular damage. In 
earlier studies in DSS-induced colitis we found a marked decrease of contraction 
by carbachol (CARB) and salbutamol (SALB)-derived relaxation in longitudinal 
colon segments 49. 
In chapter 5, in an organ bath model with longitudinally mounted transverse 
colon segments from BALBlc mice with superficial, sub-acute DSS-induced 
colitis, a diminished susceptibility for CARB and SALB was found, as reflected 
by an increase of the dose inducing half-maximum contraction 01' relaxation 
(EC50CARB and EC50SALB). This may contribute to proximal colon stasis, as is 
observed in human ulcerative colitis. The DSS-induced decrease of 
contractibility may reduce colon reservoir function, which largely depends on 
longitudinal muscle length (cylinder volume = 1<r2·O.5h). SMS in the normal mice 
diminished EC50cARB values. In the inflamed colon SMS 01' octreotide returned 
EC50cARB values to normal, thus preserving smooth muscle contraction 
susceptibility. EC50SALB increased by one week of DSS exposure. Octreotide 
did not influence this value. SMS enhanced EC50SALB both in control and 
inflamed mice, reducing p-adrenergic receptor sensitivity. SMS-induced increase 
of EC50sALB value might promote smooth muscle contractile activity in DSS-
induced colitis as well. As the muscular layer in DSS-induced colitis is intact, 
this modulation of smooth muscle contraction agonist and antagonist 
susceptibility should concern the muscarinic and p-adrenergic receptor 01' post-
receptor events. SMS has its own receptors (SSTR type 1 to 5) and interference 
with muscarinic 01' adrenergic receptors is most likely at the post-receptor level, 
like competition for same cell membrane bound G-proteins 01' intracellular cyclic 
AMP 01' cyclic GMP49.;'. 
123 
Chapter 8 
Parallel to a decreased concentration of SMS an upregulation of SMS receptor 
(somatostatin receptor, SSTR) expression has been found at specific sites in the 
inflamed intestinal wall. SSTR are cell membrane bound. In autoradiographic 
studies these SSTR are found at vascular stmctures near sites of inflammation in 
the IBD gut wall52.", not speciJYing receptor subtypes. Although it is not fully 
understood yet, the type 2 and 3 receptor might be the most impOitant SSTR in 
gastrointestinal tissue, and octreotide has high affinity for SSTR254• SSTR type 2 
can be visualised by octreotide scintigraphy, which is by now a valuable method 
of in vivo SSTR detection in neuroendocrine tumors and several granulomatous 
diseases. Results of receptor studies are described in chapter 6. Scintigraphy was 
performed with [II I In-DTPA-D-Phe I j-octreotide, that normally does not show 
intestinal wall uptake. Enhanced bowel radioactivity was observed in patients 
with active IBD. No relation was found between clinical, endoscopic or 
histologic disease activity. In vitro immunohistochemistry using a polyclonal 
rabbit anti-somatostatin receptor 2A antiserum reveiled SSTR at the intestinal 
superficial and crypt epithelium cells and endothelial cells of active inflamed 
intestinal sites. SSTR were also found at fibroblast-like cells, especially in 
ulcerative colitis. Upregulation of SSTR can be a result of feedback from the 
decreased intestinal SMS concentration in inflammation. As these studies were 
purely descriptive, there only can be speculation on the function of tlus SSTR 
expression. SMS could impair endothelial proliferation" or endothelial leukocyte 
adherence in IBD56. Vascular SSTR may playa role in SMS-derived prevention 
of intestinal ischemia', which could benefit intestinal regeneration. 
In chapter 7, in a multi-centre trial the effect of octreotide in severe human 
ulcerative colitis, treated with high-dose corticosteroids, was studied in 42 
patients. Subcutaneous administration of 500 fIg octreotide thrice daily during the 
first three weeks of therapy did not show differences fi'om placebo. No 
differences were seen between octreotide and placebo treatecl subjects in clinical 
or endoscopic response. A tendency towards quicker resolving of abdominal 
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tenderness was seen in the octreotide group. Based on these results, at tltis point 
octreotide can not be recommended as adjuvant to corticosteroids in severe 
ulcerative colitis, although it may possibly be helpful! in reducing abdominal 
pain in these patients"·'9. The benefit of SMS analogues on prevention of IBD 
exacerbations, fistula and fibrosis development and dia1'l'hoea in IBD could 
possibly be evaluated in future trials. The recent introduction of the 
microencapsulated octreotide acetate, which provides long-term octreotide 
release liOln a single intramuscular injection once in a month, is an attractive 
alternative to the present formulation and could make future studies more easy to 
perform. 
A weave of immune processes, including a very large number of cytokines, 
eicosanoids, neuropeptides and other soluble messengers, mediates intestinal 
inflammation. SMS is a single component of these combined, intricate processes. 
In active IBD, SMS receptor expression seems enhanced, as shown either by 
immunohistochemistry or octreotide scintigraphy. Octreotide scintigraphy does 
not appear to be suitable for monitoring disease acitivity, as enhanced uptake 
does not seem related with endoscopic or histologic grading of inflammation. 
SMS may prevent acute intestinal inflammation. However, both in animal and in 
human colitis, treatment with SMS or the long acting SMS analogue octreotide 
did not attenuate already active inflammation. SMS therefore cannot at present 
be recommended for the treatment of ulcerative colitis. Its potential in 
modulation of disturbed motility and the application in patients with intestinal 
fistulae deserve further study, as does the more speculative possible indication as 
preventing rather than treating relapses and influencing malignant degeneration 
in chronic colitis. 
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Samenvatting en discussie ' 
Het nellropeptide somatostatine (SMS) heeft een voornamelijk remmend effect 
op tal van biologische processen. Het komt vooral voor in het centrale en perifere 
zenllwstelsel, het illnnullllsysteem en het spijsverteringsstelsel. Uit verscheidene 
studies, zowel in vitro als in vivo, blijkt dat SMS betrokken is bij diverse 
ontstekingsprocessen. In dit proefsc!n'ift wordt onderzocht of SMS een rol speelt 
bij ontstekingsprocessen van het darmstelsel, meer in het bijzonder van het colon. 
Daarbij is llitgegaan van de gedachte dat SMS of analoge preparaten wellicht van 
belang kllllllen zijn bij behandeling van inflannnatoire darmziekten 
(inflammatory bowel disease, ]BD), zoals colitis ulcerosa en de ziekte van 
Crohn. Uit de literatuurstudie in hoofdstuk 2 blijkt dat SMS de vrijmaking van 
cytokines uit diverse imlllunocyten, waaronder intestinale epitheliale Iymfocyten, 
vermindert. SMS en SMS-analoga rem men ontstekingsprocessen in diverse 
diermodellen'·3. De hoeveelheid SMS in het slijmvlies van de darm is verlaagd 
bij humane IBD, wat Illogelijk bijdraagt aan voortgaande slijmvliesontsteking. 
Receptoren voor SMS worden gevonden op de cellllelllbranen van humane 
leukocyten, zowel in het perifere bloed als in het dal'lnslijmvlies. De proliferatie 
en de galllmaglobulineproductie van intestinale leukocyten wordt door SMS 
geremd, zoals blijkt uit verscheidene ill vitro experimenten. In een diermodel 
waarin colitis wordt veroorzaakt door azunzlIur, brengt het lang-werkend SMS-
analogon octreotide de intensiteit van darlllontsteking temg3. Daarbij daalt de 
con centra tie van secundaire ontstekingslllediatoren (platelet activating factor, 
lellkotriene B4) in het colon. Dit kan het gevolg zijn van dirccte interactie van 
octreotide met immunocyten, maar oak door invloed op niet-immunologische 
processen. Octreotide onderdrukt nalllelijk ook de secretie van proteolytische 
pancreasenzymen, waardoor de gevoeligheid van colonslijmvlies VOOI' azijnzlIur 
wellicht afneemt4.'. Daamaast zijn uit onderzoek bij experimentele pancreatitis 
cytoprotectieve effecten vall SMS bekend6 . Ook de invloed op doorbloeding kan 
. voor referenties en figuren: zie Chapter 8 
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een beschennende rol spelen, zoals bij experimentele pancreatitis, in modellen 
van leverischemie en bij experimenteie danuischemie7-9, 
Wanneer knaagdieren via hun drinkwater worden blootgesteld aan dextraan-
natritllnsulfaat (dextran sulphate sodium, DSS) in bepaalde concentraties, 
ontstaat een vrij milde colitis. Dit colitismodel is goed reproduceerbaar en heeft 
kenmerken van colitis ulcerosa (TABEL 8.1). De studies uit dit proefschrift 
bctreffen een muismodel (BALB/c muis), waarin colitis wordt veroorzaakt door 
DSS 10 % (gewicht/volume) in drinkwater. DSS-colitis wordt gekenmerkt door 
toegenomen mucosale influx van neutrofiele granulocyten, verstoorde 
cryptarchitectuur en verlies van slijmbekercellen. De ontsteking is doorgaans 
mild en betreft de oppervlakkige slijmvlieslagen. Granulomen worden luet 
aangetroffen. Meestal is het gehele colon ontstoken, maar in tegenstelling tot 
colitis ulcerosa wordt aangedaan met normaal slijmvlies frequent afgewisseld. 
Net als bij humane colitis ulcerasa is bij acute DSS-colitis de con centra tie van 
interleukine-IO (IL-lO) colonslijmvlies verlaagd. Dil ontstaat mogelijk door 
verminderde activiteit van T-helper2 ('fH2)-lymfocyten lO • Bij chronische DSS-
colitis blijkt een verhoogde nl!-fiUlctie li . Nog niet alles is bekend van de 
pathogenetische mechanismen van DSS-colitis. Aangenomen wordt dat DSS de 
functie van colomnacrofagen beperkt (FIGUUR 8.1)!2,13. In hoofdstuk 3 en 4 
wordt steun gevonden voor deze hypothese. Er treedt een verlaging op van het 
voornamelijk door macrafagen gepraduceerde IL-6 in het colonslijmvlies bij 
DSS-colitis. Oit staat in contrast met verhoogde IL-6 concentraties in 
colonmucosa en darminhoud bij colitis ulcerasa!4,!,. Verminderde activiteit van 
macrofagen geeft dannbacterien kans de colomnucosa binnen tel' dringen, wat 
leidt tot slijmvliesontsteking!6.17. Daamaast bestaat de mogelijkheid dat DSS de 
permeabiliteit van het colonslijmvlies vergroot!8. Ook zouden extra-intestinale 
delen van het innnuunsysteem bij het ontstaan van DSS-colitis betrokken kunnen 
zijn, waarbij darmontsteking dool' invloeden vanuit het perifere bloed ontstaat. 
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Betrokkenheid van organen als thymus en milt komt echter niet naar voren uit 
onze studies. 
Er zUn aanwijzingen voor betrokkenheid van het enterale zenuwstelsel c.q. 
enterale nelll'opeptiden bij DSS-colitis. De emst van deze colitis neemt toe 
wa/ll1eer capsaIcine de uiteinden van enterale zenuwcellen beschadigtl9. Het is 
evenwel niet bekend of SMS betrokken is in DSS-colitis. In een ander 
ontstekingsmodel, met acute, hevige colitis door trinitrobenzeen sulfonzulll', is 
het SMS-gehalte van het colon slechts licht verlaagd20 . Andere neuropeptiden 
(substance P, vasoactive intestinal peptide, calcitonin gene related peptide) 
hebben een ontstekingsbevorderend eflect in verscheidene ontstekingsmodellen 
en mogelijk ook bU lBD2l•26 • SMS antagoneert in sOimnige opzichten het pro-
inflanll11atoire effect van substance p27. 
Zoals in hoofdstuk 3 wordt besclll'even, heeft SMS een preventief effect op de 
influx van neutrofiele granulocyten in het colonslijlllvlies. Hierdoor daal! de 
histologische ontstekingsscore van DSS-colitis. Het onderliggende mechanisme 
is nog onbekend. Uit de literatuur komen tegengestelde berichten over de illvloed 
van SMS op migratie van leukocyten naar voren. Zowel renlllende als 
stimulerende effecten worden besclll'even"·3l. SMS kan mogelijk interfereren 
met leukocytenadhesie32.J4, zoals door verlaging van adhesiemoleculen35•36• Uit 
onze studies blijkt geen direct remlllend effect van SMS op intestinale 
IYlllfocyten, omdat T-Iymfocyt-afllankelijke cytokineproductie niet wordt 
beYnvloed. Reeds door DSS verlaagde IL-6 waarden in het colonslijmvlies 
worden nog lager na toedienen van SMS. nat kan samenhangen met een 
remmend effect op macrofagenactiviteit, zoals eerder door anderen 
gerapPOlteerd37•38• 
SMS noch octreotide zijn van invloed op ontstekingsactiviteit in sub-acute DSS-
colitis, die ontstaan is na 7 dagen nss toediening (hoofdstuk 4). Er is zelfs enige 
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toename vanncutrofiele granulocyten in het colonslijmvlies van muizen die SMS 
of octreotide kregen zonder blootstelling aan OSS. Zoals him'boven reeds 
vermeld, is dit een merkwaardige tegenstelling tot eerdere bevindingen bij de 
acute OSS-colitis. In dit stadium van OSS-gernduceerde colitis lijkt interferon 
(IFN)-y geen belangrijke rol te spelen, getuige de niet te detecteren wam'den in 
het colonslijmvlies. SMS en octreotide brengen de reeds verlaagde spiegels van 
IL-I p, IL-6 en IL-lO bij sub-acute OSS-colitis verder terug. Oit kan wijzen 01' 
DI,-dysfunctie door toediening van SMS. IL-IO speelt een rol bij 
darmontstekingen39"O en heeft mogelijk een heilzame werking bij OSS-colitis en 
humane IBO iO,'l,'2. Een verlaagde IL-IO concentratie zou mogelijk in de post-
acute fase van OSS-colitis een ontsteking in de hand klllll1en werken, Toekomstig 
onderzoek zou de invloed van SMS 01' secundaire ontstekingsmediatoren 
(prostaglandines, leukotrienen, stikstofoxide) bij OSS-colitis kunnen belichten, 
evenals de invloed 01' ontstekingsintensiteit bij cln'onische OSS-colitis, die 
ontstaat door herhaalde blootstelling aan DOS alternerend met normaal 
drinkwater. In dit verband is ook de ontwikkeling van coloncarcinomen tij dens 
langeI' bestaande OSS-colitis interessant43 ,44, SMS-analoga rennnen groei van 
adenocarcinoma 45,46. 
Bij IBO patienten is frequente defaecatie vaak lastig te behandelen. Uit diverse 
klinischc studies blijkt een gunstig effect van octreotidetoediening 01' moeilijk te 
behandelen dianee". Oaarbij wordt mogelijk de secretie van dannsappen, de 
activiteit van enterale zenuwcellen of intestinale gladde spiercellen belnvloed. 
Het meeste onderzoek IlCeft zich geconcentreerd 01' dunne darmsecretie en -
motiliteit. SMS wordt toegepast bij behandeling van dial'!'ee bij de ziekte van 
Crohn van de dunne dann". Een eventuele toepassing bij colitis ulcerosa is nog 
onbekend. Het OSS-colitismodel is geschikt voor onderzoek naar fimctie van 
gladde spieren van het colon door ontsteking, vanwege de oppervlakkige 
weefselschade, waarbij de colomnusculatuul' geheel intact blijft. Uit eerder 
onderzoek bij OSS-colitis blijkt een duidelijke afname van contractie door 
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carbachol (CARE) en relaxatie door salbutamol (SALB) van longitudinale 
colonsegmenten49• 
In een orgaanbadopstelling worden longitudinale colonsegmenten uit een muis 
met sub-acute DSS-colitis onderzocht, zoals beschreven in hoofdstuk S. Er is een 
verminderde gevoeligheid voor CARE en SALB, zoals blijkt uit een toename 
van de dosis die SO% van de maximale contractie respectievelijk relaxatie geeft 
(ECSOCARB en ECSOSALB). Een relatieve ongevoeligheid voor contractie-
agonisten geeft stase van de coloninhoud, wellicht equivalent aan de toename 
van proximale colon transit tijd bij humane colitis ulcerosa. Daarnaast leidt 
vermindering van contractiliteit van het colon transversum tot verminderde 
colonreservoirfunctie, die onder meer afbankelijk is vanlongitudinale spierlengte 
(cilinder volume = nr'·O,Sh). SMS verlaagt de ECSOCARB bij controle muizen 
zonder DSS-colitis. De bij DSS-colitis verlaagde waarde van deze parameter 
nonnaliseert door SMS en octreotide, zodat de gevoeligheid voor contractie 
bewaard blijft. ECSOSALB neemt toe na een week DSS toediening. Octreotide is 
hierop niet van invloed. SMS verhoogt de ECSOSALB in normale muizen en 
muizen met DSS-colitis, daat'l1lee de gevoeligheid voor p-adrenerge middelen 
verlagend. Deze door SMS verlaagde gevoeligheid voor relaxerende invloed kan 
ten goede komen aan de coloncontractiliteit bij colitis. Omdat de spierlaag van 
het colon bij DSS-colitis optisch intact is, zijn de waargenomen veranderingen 
niet veroorzaakt door beschadigde spiercellen, maar lijken ze samen te hangen 
met receptordisfunctie of met post-receptoreffecten. SMS wordt gebonden aan 
eigen, specifieke receptoren (SST type I tot S). Interferentie met muscarine- of 
adrenerge receptoren geschiedt waarschijnlijk op post-receptorniveau, door 
bijvoorbeeld competitie voor dezelfde celmembraangebonden G-protelnen of het 
intracellulaire cyclisch AMP ofGMP49-51 • 
In ontstoken dannweefsel word! naas! een verlaagde SMS-concen!ra!ie een 
verhoogde hoeveelheid SMS-receptoren (SST) gevonden op de membranen van 
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diverse celtypes. SST worden met autoradiografie, waarbij receptorsubtypering 
meestal niet mogelijk is, gevollden op vaten rolld ontstekingshaarden in de 
darmwand bij IBD52.'3. Alhoewel nog niet alles daarover duidelijk is, lijken de 
SST typen 2 en 3 (SST2 en SST3) het meest 1'001' te komen in gastro-intestinaal 
weefsel. Octreotide heef! grote affiniteit voor SST254• SST2 kan gevisualiseerd 
worden door middel van octreotidescintigrafie. Dit onderzoek is een gevalideerde 
methode voor ill vivo detectie van SST-positieve haarden bij neuro-endocriene 
tumoren en diverse granulomateuze ziekten. Resultatell van receptorstudies 
worden beschreven in hoofdstuk 6. Scintigrafie werd uitgevoerd met [llIIn_ 
DTPA-D-Phe1j-octreotide, dat normaliter niet in de danuwand wordt 
opgenomen. Toegenomen activiteit van eIIIn-DTPA-D-Phel]-octreotide is 
zichtbaar in het darmstelsel van patienten met actieve IBD. Er is geen relatie 
gezien tussen de klinische, endoscopische of histologische activiteit enerzijds en 
de scintigrafische activiteit anderzijds. Immunohistochemie ill vitro, met behulp 
van een polyklonaal konijnen anti-somatostatine receptor 2A antiserum, liet 
aanwezigheid van SST zien op het intestinale opper1'lakkig- en cryptepitheel en 
endotheel nabij ontstekingshaarden. SST worden ook gezien op fibroblast-
achtige cell en, in het bijzonder bij colitis ulcerosa. Toename van SST zou een 
gevolg kunnen zijn van een positieve feedback door dalende SMS concentratie 
bij ontsteking. Vanwege de descriptieve aard van de studie kan slechts 
gespeculeerd worden over de funetie van deze SST expressie. Van SMS wordt 
inhibitie van endotheliale proIiferatie" en -leukocytenadherentie" bij IBD 
bescln·even. Wellicht spelen de vasculaire SST een rol bij de aan SMS 
toegescln'even preventie van ischemie7, daarmee intestinale regeneratie 
bevorderend. 
In hoofdstuk 7 wordt een multi-centre studie beschreven waarin octreotide werd 
toegediend bij 42 patienten met ernstige colitis ulcerosa, tevens behandeld met 
hoge doses corticostero¥den. Driemaal daagse, subcutane toediening van 500 llg 
octreotide gedurende de eerste drie weken van behandeling toont geen 
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verschillen met placebo, zowel in klinisch, als in biochemisch of endoscopisch 
opzicht. WeI bestaat er bij de met octreotide behandelde groep een trend tot 
snell ere vermindering van buikpijn. Omdat de studiegroep relatief klein is, kan 
op grond van de resultaten van deze studie het gebl1lik van octreotide als 
aanvulling bij de behandeling van ernstige colitis ulcerosa met corticosteroiden 
vooralsnog niet worden aanbevolen. Interessant is wel een mogeJijk gunstig 
effect op de buikpijn bij IBD, dat misschien perspectieven biedt voor verder 
onderzoek"·59. In toekomstig onderzoek zou ook het potentiele effect van SMS-
analoga bij preventie van IBD-exacerbaties, preventie van fistelvorming en 
ontwikkeling van fibrose en dianee bij IBD onderzocht kunnen worden. De 
recente introductie van het ultralang-werkende octreotide-acetaat, dat eenmaal 
per maand intramusculair kan worden toegediend, kan daarbij belangwekkende 
ontwikkeling zijn. 
Intestinale ontsteking wordt onderhouden door een ingewikkeld en bijzonder 
uitgebalanceerd netwerk van immuunprocessen, waarin naast ceHulaire 
onderdelen, diverse cytokines, eicosanoYden, neuropeptiden en andere 
moleculaire mediatoren een 1'01 spelen. SMS neemt maar een kleine plaats in in 
dit geheel. Bij actieve IBD lijkt er een verhoogde SST2 expressie te bestaan. 
Octreotidescintigrafie is niet geschikt om bij IBD de ziektelokalisatie of -
activiteit te duiden, wegens ontbreken van duidelijke relaties met histologische of 
endoscopische bevindingen. Acute ontsteking kan met SMS wellieht voorkomen 
worden. Daarentegen heeft het SMS-analogon octreotide geen bewezen gunstig 
effect bij behandeling van reeds aan de gang zijnde colitis, zowel in het OSS-
ll1uismodel als in de mens. Dam'om kan SMS niet worden aanbevolen als 
ontstekingsremmende therapie bij IBO. Potentiele bemvloeding van verstoorde 
darillmotoriek en bijvoorbeeld fistelvorming verdient nader onderzoek, evenals 
preventieve c[fecten bij exacerbaties van IBD en maligne degeneratie van 
colonslijmvlies bij clu'onische colitis. 
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Het schrijven van een proefschrift is geen eenmansactie. Aan de vOOligang van 
dit werk hebben velen bewust of onbewust een bijdrage geleverd, waarvoor ik 
zeer dankbaar ben. Enkele mensen, die zich bijzonder hebben ingezet vaal' het 
slagen van dit project, wil ik bij name noemen. 
Mijn promotor, profJ.H.P.Wilson, wil ik dallken Vaal' de steUlI en het vertrouwen 
bij het ontwikkelen van de ideeen en proto collen. Beste Paul, je vermogen tot 
snel verkrijgen van overzicht, je humor en je relativerende opmerkingen zijn 
verkwikkend en stimulerend en hebben op een plezierige wijze de richting van 
mijn onderzoek aangegeven. 
De copromotor dr.F.J.Zijlstra, was onmisbaar Vaal' het farmacologische 
onderdeel van dit werk. Beste Freek, ik heb veel tijd van je gevraagd en 
gekregen. Je gedegen vakkemlis was Vaal' mij van grote waal·de. Bovendien wist 
je me op het juiste moment een hart onder de riem te steken. Ik hoop dat ollZe 
strategische alliantie niet met het verschijnen van dit proefschrift ten einde is 
gekomen. 
Prof.dr.S.W.J.Lambelis, prof.dr.P.R.Saxena en dr.ir.H.W.Verspaget, de leden 
van de kleine commissie, wil ik danken Vaal' de beoordeling van het manuscript. 
Zander de hulp van Jeanet van Dijk, COl'lle Tak en Marieke van Meeteren van de 
Vakgroep Fannacologie, was er niets op papier gekomen over muizen, modellen 
of mediatoren. Jullie inspmlllingen bij het homogeniseren van muisweefsel, het 
inzetten van assays en de verwerking dam'van waren geweldig. Jeanet, mijn 
onhandigheid bij het vervaardigen van histologische coupes wenl l1limschoots 
gecompenseerd door je geduld en optimisme. 
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Dr.P.M.van Hagen ell dr.D.J.Kwekkeboom, beste Martin, beste Dik, ik dank 
jullie voor de tijd die gefnvesteerd is in het opzetten, bewerken en beoordelen 
van scintigrafische en immunohistochemische bevindingen. In deze dank wil ik 
ook mw.A.M.C.ten Bokum en mw.dr.C.M.Mooy van de afdelingen inununologie 
en pathologic betrekken. Mw.M.Bendik was van bijzondere hulp. Beste Mmja, 
dankzij jouw ervarillg en inzet zou het eoordineren van diverse studies, 
waaronder OPUS I, onmogelijk geweest zijn. 
De hulp van de paranimfen Maarten Meijssell en Jan Uil strekt zieh uit al vel' 
voor het voleindigen van dit proefschrift. Beste Maartell, je hebt al mijn 
protocollen en schrijfsels gelezen en waar nodig - en dat was regelmatig - van 
kritiseh COIlUllelltaar voorzien. Je loyaliteit, collegialiteit en vrielldschap stel ik 
zeer op prijs. Beste Jan, je humor ell relativeringsVel'lllOgen getuigell van een 
verfi'issende kijk op werk, wetenschap en maatschappij. Je mening, die je 
doorgaans niet onder stoelen of banken steekt, wam'deer ik te allen tijde. De 
dagelijkse samenwerking met Ben Witteman en jou schaft veel genoegen. 
De opleiders in Arnhem (dr.C.van GasteI, dr.J.M.Werre) en Rotterdam (M.van 
Blankenstein en prof.dr.S.W.Schalm) ben ik dankbaar VOOl' het Ieggen van een 
solide kliniseh-wetenschappelijke basis in de intel'lle geneeskunde en 
hepatogastro-enterologie. Daarbij mag de inbreng van dr.C.J.J.Mulder niet 
onvermeld blijven. Beste Chris, je hebt je steeds bekonmlerd om mijn 
wetenschappelijk welbevinden. Helaas lijkt eoeliakie een voomamelijk Oost-
Nederlands ziektebeeld en mijn aanwezigheid ill Rotterdam heeft dam'aan mets 
veranderd. 
De stafledell van de afdeling MDL ben ik dankbaar voor hun belangstelling en de 
tijd die ik voor mijn onderzoek mocht geb1'lliken. Het person eel van de GE-
eelltrale dank ik VOOI' de gezelligheid, het morele support en de hulp bij 
verzamelen van materiaal, zowel in biologische als administratieve zin. 
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Familie en vrienden dank ik vom de mst. Ik ben er weer en ik hoop dat je het 
verschil zult merken. Onze wederzijdse ouders dank ik Vaal' de aandacht en 
aalllnoediging, die ik tijdens studie en opleiding steeds mocht ontvangen. Beste 
vader, door je in te lezen in de literatuur rond mijn onderzoek was je een 
belangrijk en stimulerend klankbord Vaal' ideeen en scln·ijfoefeningen. 
Lieve Jacqueline, onvolprezen socia Ie manager van ons gezin. Het is te dalll<en 
aan jouw slimulerende en liefdevolle inzet dat de ali'onding van dit proefscln'ift 
in deze fase van ons leven is gelukt. Het rei zen is over, we blijven in de Gelderse 
Vallei, jij bent aan zet. Thomas, Jorne en Stijn, die vreselijke computer mag ntl 
ook Vaal' spelletjes gebruikt worden en die gaan we samen doen! 
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Curriculum vitae 
De auteur van dit proefschrift werd geboren op I april 1962 te Barendrecht. Na het 
examen VWO-B aan het Christelijk Atheneum te Arnhem in 1980 volgde de studie 
Geneeskunde aan de Katholieke Universiteit van Nijmcgcn (doctoraal examcn: maart 
1985, misexamen: febl1lari 1988). In 1987 werd het co-assistentschap Sociale 
Gcnceskunde vervuld in Lesotho, Afrika. Na het at1sexamen was de auteur werkzaam 
als AGNIO bij het Universitair Longcentnlll1 Nijmegen (prof.dr.C.L.A. van 
Her\Vaarden) van maart 1988 tot juni 1989. In die periode was hij tevens tijdelijk 
werkzaam als wetenschappelijk docent bij de Vakgroep Fysiologie, scetie 
InSpaIUlillgsfysiologie van de Medische Faculteit, Katholieke Universiteit te Nijmegen 
(prof.dr.R.A.Binkhorst). Daama voIgde de opleiding tot intemist in ziekenhuis Rijnstate 
te Anlhem vanjllni 1989 tot mei 1993 (dr.C.van GasteI, dr.J.M.Werre). Deze opleiding 
werd voortgezet in de Kliniek voor Inwcndige Ziektcll van het Academisch Ziekenhuis 
te Nijmegen (prof.drJ.W.M.van der Meer) tot mei 1994, met een stage gastro-
enterologie in Rijnstate te Amhem (dr.C.JJ.MuIder), en bij de Afdeling Interne 
Geneeskunde II van het Academische Ziekenhuis Rotterdam (profJ.H.P.Wilson). 
Inschrijving als intcmist in het specialisten register vond plaats op 12 jUlli 1995. In het 
Acadcmisch Ziekenhuis Rotterdam werd ook de opJeiding tot maag-, darm- en leverar1s 
gevolgd bij de gastro.enterologen M.van Blankenstein en prof.dr.S.W.SchaIm 
(registratie gastro-enterologie op I september 1997). In deze periode nam hij aIs 
internist deel aan het level1ransplantatieteam van het Academisch Ziekenhuis 
Rotterdam. Tijdens de opleiding gastro-enterologie werd eell aanvang gemaakt met het 
onderhavige promotieonderzoek (prof.l .H.P. \Vilson), dat deels onder leiding van 
dr.FJ.Zijlstra werd uitgevoerd op de Vakgroep Fannacologie van de Faculteit 
Geneeskunde en Gezondheidswetenschappen van de Erasmus Universiteit te Rotterdam. 
Betrokkene was daama werkzaam als tijdelijk staflid op de Afdeling Interne II, Sectie 
Gastro-enterologie en waalllemend gastro-enteroloog op de Afdeling Interne Oncologie, 
locatie DDH, van het Academisch Ziekenhuis Rotterdam. Vanaf 1 februari 1998 maakt 
hij als gastro-enteroloog deel nit van de Maatschap Inteme Geneeskunde en Gastro-
enterologie in het ziekenhuis Gelderse Vallei, locatie \VageningenlBennekom. Hij is 
getrouwd met Jacqueline Heitink. Zij hebben 3 zonen: Thomas, Jome en Stijn. 
143 

